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 Progression through the mitotic stage of the cell cycle is regulated by 
several checkpoint mechanisms to ensure equal chromosomal segregation. 
Abnormalities during mitosis can result in the gain or loss of chromosomes, 
a condition known as aneuploidy. The ability to proliferate despite abnormal 
chromosomal copy number is a key hallmark of human cancers, and how 
cancer cells override cellular checkpoints is a key area of interest. Post-
translational protein modifications such as phosphorylation drive mitotic 
entry and progression, while the ubiquitin-mediated targeting of proteins 
facilitates exit from mitosis. Here we present the functional requirement of 
another post-translational modification known as the Small Ubiquitin-related 
Modifier (SUMO). While the history of SUMO discovery is tied to functions 
in regulating mitotic progression, here we present a novel role for SUMO 
modification in regulating the activity of an E3 ubiquitin ligase known as the 
Anaphase Promoting Complex/Cyclosome during the metaphase-anaphase 
transition. Further characterization on the SUMO isopeptidase SENP1 
during different stages of the cell cycle is also presented herein. Taken 
together, this thesis provides additional insights to the regulatory roles of 
how a small protein can have profound effects on cellular function. 
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 Graduate school can be compared to marathon training in many ways. 
In the beginning, the steep gradients ahead seem insurmountable (like the 
backroads of Druid Hill Park, imposing vertical challenges) or your body 
negatively reacting to the heat or cold (there is nothing like the dread of 
finding your protein precipitated out after a careful purification scheme—the 
chill of the cold room adding a sharp pang to your already shivering heart). 
But through persistence and patience, sparks of wonder are revealed: the 
connection of a new roadway to a familiar, well-beaten path, or the covalent 
modification of a substrate by a small, but powerful protein.  
 Luckily, Mike Matunis is a coach with multitudes of insights. Thank 
you, Mike, for your unrelenting support and guidance during my graduate 
studies. I am pretty sure you’ve never said “no” to any of my ideas, whether 
whimsical or just wrong. With patience and careful instruction, you’ve 
taught me to consider all of the caveats and proper controls so that every 
experiment, even with “negative” data, reveals important scientific truths. I 
have enjoyed the fullest training available to graduate students, with multiple 
opportunities to learn new techniques in other labs, to travel and present at 
meetings, and to communicate science through several outlets and to various 
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audiences. Truly, I feel that no indulgence was spared, and cannot imagine a 
more supportive or nurtured environment in which to develop as a scientist. 
 Several adages of wisdom will henceforth guide my approaches in 
science and in life, ones that all Matunis Lab alum have canonized: The 
control for the experiment you performed last week cannot be the control for 
the one you perform today; if you don’t have time to fully do the right 
experiment today, when will you have time to repeat it? and the excited 
battle cry to go for the jugular! Perfecting the Matunis Code of Aesthetics 
(Ariel bold font, centered straight lines, and “beautiful” immunoblotting) has 
appealed to my neuroses. In the pursuit of these standards, I have 
experienced the private delight inside the film developing room, underneath 
the dim red glow of an unexpected result, and learned the value of clarity in 
presenting both oral and written work. Thank you, for all of the 
opportunities.  
 I would also like to thank the core members of my Thesis Advisory 
Committee, Dr. Andrew Holland, Dr. Phil Jordan, and Dr. Daniela 
Drummond-Barbosa. We had the great fortune in initiating a project 
concerning the mitotic stage of the cell cycle coincidentally with the arrival 
of two energetic experts in their respective fields, Andrew and Phil. Your 
perspectives and recommendations, and share of reagents and tools, have 
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driven the depth and rigor of our studies from the very beginning. I am also 
grateful to Daniela for careful reading of this thesis, for always centering my 
focus to a strong biological context, and her thoughtful and careful guidance 
both professional and personally. Furthermore, I want to acknowledge and 
thank members of the Hopkins Ubiquitin Club and the PJAMMa meetings 
for teaching me scientific findings that are fascinating, exciting, and fun. 
 I also want to thank the members of the Matunis Lab – near and far, 
former and current. Thank you all for your patience in instruction of 
techniques and also for your warmth in friendship. To my classmates and the 
BMB department as a whole – thank you all for your words of 
encouragement, advice, and generosity. To the administrate and house staff, 
including Sharon Warner, Shannon Gaston, Mystee Edmonds, Kear Wright, 
Erika Vaitekunas, Jackie and Karen – thank you for all of your work behind-
the-scenes so that each day runs smoothly and cleanly. I have enjoyed the 
great privilege of having a truly collaborative department where colleagues 
are more like extended family. One of these days I will remember to make 
my own stock of Kanamycin-selection agar plates. 
 Finally, I want to thank my parents and family for their commitment 
in supporting my education at every level. None of my achievements would 
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have been possible without your countless and continual sacrifices. And to 
Bing – I’m sorry for all that I’ve said when I was hungry. 
 
See enough and write it down, and then some morning when the 
world seems drained of wonder, there it will all be, a forgotten 
account with accumulated interest, paid passage back to the 
world out there. 
- Joan Didion, On Keeping a Notebook, 1966 
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CHAPTER 1:  
INTRODUCTION
21 
The SUMO Protein and Pathway 
 
 The Small Ubiquitin-related Modifier, or SUMO, is a ~12 kDa protein 
that is post-translationally added to substrates. Components of the SUMO 
pathway are well conserved from yeast to humans, with essential roles in a 
variety of cellular processes including transcription, chromatin remodeling, 
ribosome biogenesis, and DNA damage repair1. While thousands of SUMO 
substrates have been identified through proteomic studies, the steady state 
level of a SUMO modified protein is relatively low due to the dynamic 
activity of conjugating and deconjugating enzymes. Nonetheless, SUMO 
modification can abrogate or cooperate with other post-translation 
modifications such as acetylation and ubiquitylation to affect downstream 
cellular processes. Functionally, sumoylation can direct localization of 
substrates or generate novel non-covalent interactions with proteins 
containing SUMO Interacting Motifs (SIMs)2. This thesis will discuss one of 
the conserved roles for SUMO modification in regulating cell cycle 
regulation, as perturbations to components of the SUMO pathway in all 
eukaryotes cause aberrations in mitosis. 
 Analogous to other members of the ubiquitin-like family of proteins, 
SUMO is translated as an immature precursor, and must be processed by 
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isopeptidases to expose a C-terminal di-glycine used for conjugation to the 
e-amine of the substrate lysine3,4. In yeast3,5,6, C. elegans7, D. melanogaster8, 
and even P. falciparum9, a single SUMO gene is expressed, while 
vertebrates express three functional SUMO isoforms, SUMO1, SUMO2 and 
SUMO34. SUMO1 is ~45% identical to SUMO2 and SUMO3, while 
SUMO2 and SUMO3 share ~96% sequence homology and are collectively 
referred to as SUMO2/3 (Figure 1-1). SUMO proteins can also be post-
translationally modified by phosphorylation, ubiquitylation, and 
acetetylation, thus generating diverse signals10 (Figure 1-1). Furthermore, 
SUMO2/3 contain a SUMO consensus site motif enabling the formation of 
polymeric SUMO chains (Figure 1-1) with potentially unique signaling 
properties. 
 SUMO modification occurs through an ATP-dependent enzymatic 
cascade involving the sequential activity of an E1 activating (expressed as 
the heterodimer Aos1/Uba2 in humans), an E2 conjugating (Ubc9), and 
several E3 ligating enzymes (Figure 1-2, Table 1-1). Compared to the 
ubiquitin system, SUMO conjugating machinery is relatively limited. While 
the ubiquitin system has ~40 E2 conjugating enzymes and over 600 
identified E3 ligases which function to specify substrate selectivity, the 
catalog of enzymes in the SUMO system is comparatively small11. SUMO 
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modification is nonetheless an essential process and produces profound 
effects on protein function.   
 A majority of SUMO substrates are modified at lysine residues within 
the consensus site y-K-x-E/D motif, whereby y represents a hydrophobic 
residue, K is the substrate lysine, x is any amino acid, followed by an acidic 
residue, either glutamic or aspartic acid4,12. An additional SUMO consensus 
site motif incorporating post-translational modification by kinase activity is 
defined as a phosphorylation-dependent SUMO motif (PDSM), with an 
amino acid sequence y-K-x-E/D-x-x-S-P13.  
 
SUMO in Eukaryotes 
 The single SUMO gene in S. cerevisiae was first identified in a 
genetic screen for mutants that suppress MIF2 (Mitotic fidelity of 
chromosome transmission), which is an ortholog of the human centromere 
protein CENP-C4. MIF2 results in mitotic delays and defects in chromosome 
segregation and microtubule morphology, while the temperature-sensitive 
mif2-3 strain stabilized mitotic and structural stability5. Several groups 
simultaneously cloned the mouse and human homologs of SMT3 with 
variable nomenclature12. UBL1 (ubiquitin-like protein 1) and Sentrin were 
identified through two-hybrid screens for interactors of Rad51 and Rad52 
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and “death domains” in Fas/APO-1 and TNF receptor 1 as baits14,15, while 
PIC1 (PML interacting protein 1) was shown to co-localize in PD10 nuclear 
bodies16. The GTPase-activating protein RanGAP1 was the first bona fide 
substrate shown to be modified by a novel ubiquitin-related modifier, named 
GMP1 (GAP-modifying protein 1)17 and SUMO1 (small ubiquitin-related 
modifier)18. Sumoylation of RanGAP1 directs targeting to the nuclear pore 
complex (NPC) and localization to the cytoplasmic face of the NPC 
facilitates nucleocytoplasmic transport17,18. While the single SUMO gene in 
lower eukaryotes is essential, genetic knockouts of the three different SUMO 
paralogs in mice suggest some degree of functional redundancy. SUMO1 
knockout mice are viable but not without defects, suggesting that SUMO2/3 
in part can compensate for SUMO119–22. Furthermore, SUMO2 knockout 
mice are embryonic lethal while SUMO3 knockout mice are viable—further 
suggesting the compensatory capabilities and underscoring the functional 
importance of SUMO223. Paralog selectivity in response to different cellular 
stresses have also been implicated, as high molecular weight SUMO2/3 
conjugates are stimulated under conditions of heat shock or oxidative stress 
while SUMO1 levels remain relatively unchanged24. While drugs that 
selectively inhibit the formation of the E1-SUMO intermediate have been in 
development25,26, compounds directed towards the conjugation of distinct 
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SUMO paralogs will provide insights into the functional redundancy and 
cellular requirements of SUMO1, 2, and 3. 
 
SUMO Isopeptidases 
 Regulation of SUMO modification at the level of deconjugation is a 
critical axis of the SUMO pathway. SUMO isopeptidases cleave at the C-
terminal glycine of SUMO and the substrate lysine. Several classes of 
SUMO isopeptidases have been identified, beginning with the discovery of 
Ulp1 (UBL-specific protease 1) in S. cerevisiae27. Like deubiquitinating 
enzymes, SUMO isopeptidases are cysteine proteases but are unrelated in 
sequence. Interestingly, Ulp1 was found to have sequence homology and 
catalytic mechanisms similar to viral proteases27. The second family member 
was discovered shortly thereafter, and Ulp2 was characterized in S. 
cerevisiae as having important but non-essential roles in maintaining 
chromosomal stability and cell morphology28. Functionally, Ulp1 is an 
essential gene required for normal mitotic progression, as temperature-
sensitive mutants arrest during the G2/M stage of the cell cycle27. The amino 
terminus of Ulp1 is non-essential for catalysis, but directs localization that is 
functionally important for activity29. Similarly, the SUMO isopeptidases in 
humans, first identified as SENPs (sentrin-specific isopeptidase)30, contain 
conserved C-terminal catalytic domains and divergent N-terminal sequences 
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that are important for directing sub-cellular localization and activity31. The 
identification and characterization of the SENP family members demonstrate 
distinct roles for desumoylation. SENP1 and SENP2 regulate mitotic 
regulation32,33, SENP3 regulates transcriptional activity, SENP3 and SENP5 
coordinate ribosome biogenesis, while SENP6 and SENP7 have functions in 
editing polymeric SUMO chains34. Genetic knockouts of different SENP 
paralogs demonstrate the essential requirement of SUMO isopeptidase 
activity. Both SENP1 and SENP2 knockout mice are embryonic lethal at 
mid-gestation due to aberrations in cardiac development and function35,36. 
Additional classes of SUMO isopeptidases have also been identified37,38, and 
future classification on how these enzymes affect the catalog of thousands of 
SUMO substrates is of particular interest. Whether SENPs have SUMO 
paralog specificity in vivo or if substrate recognition is mediated by another 
mechanism is also a question that remains unanswered. 
   
SUMO Interacting Motifs (SIMs) 
 SUMO modification can generate novel protein-protein interactions 
between a sumoylated substrate and another protein containing a SUMO 
Interacting Motif (SIM)2. A consensus sequence for SIM binding is defined 
as a stretch of hydrophobic amino acids (V/I)-x-(V/I)-(V/I) flanked by an 
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acidic residue. The hydrophobic amino acids in SIMs interact non-
covalently with a hydrophobic pocket situated in the b2 strand on the surface 
of SUMO, creating a parallel or antiparallel b-strand conformation39,40 
(Figure 1-3). SIM motifs can facilitate efficient SUMO conjugation, as in the 
case of SIM motifs present in select SUMO E3 ligases41,42. SUMO-SIM 
interactions can also reorient structural conformations, as demonstrated in in 
vitro studies of thymidine DNA glycosylase (TDG)43. Additionally, SUMO-
SIM interactions can additively assemble protein complexes, as in the case 
of the PML (promyelocytic leukemia) protein, whereby SUMO-modified 
PML interacts with SIMs in other PML proteins to form PML nuclear 
bodies44,45. SIMs can also facilitate the recruitment of SUMO Targeted 
Ubiquitin Ligases (STUbLs)46,47 and mediate substrate targeting to the 
proteasome. In one example, SUMO is recognized by SIMs in Rap80 
(Figure 1-3), which also contains ubiquitin interacting motifs (UIMs). A 
SUMO-ubiquitin hybrid chain is assembled through the activity of RNF4, an 
E3 ubiquitin ligase that facilitates proteasomal degradation48. In addition, a 
variation on the SIM motif includes a phosphorylation site in close 
proximity to the hydrophobic residues40, which functions to specify 
interactions with substrates and enhance SIM recognition. Furthermore, a 
“code of specificity” for SIM binding partners to SUMO1 and SUMO2/3 
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provides a level of paralog selection due to differences in amino acid 
composition in the b2 strand where SIM binding occurs40. Taken together, 
the functional consequences of SUMO-SIM interactions are a feature of the 
SUMO system that facilitates functional diversity in regulating cellular 
processes.  
 
SUMO and Mitotic Regulation 
 This thesis will cover how components of the SUMO pathway 
coordinate mitotic progression. While there are many excellent reviews on 
several components of mitotic regulation49–54, a brief historical overview and 
current models will be described herein. 
 
Cell Cycle Progression is Coordinated by CDK/Cyclins and the Ubiquitin-
Proteasome System  
 The discovery of cyclin launched a series of compelling questions that 
have shaped our current understanding of how eukaryotic cells grow and 
divide. Cyclins were first observed in sea urchin eggs and named based on 
the observation that protein levels rise and fall in a pattern concomitant with 
cell divisions55. Thus, the search for regulatory controls of an intrinsic cell 
“autonomous oscillator”56 led to the discovery of cell cycle checkpoints57, 
coordinated by what is now known to be the activity of Cyclin-Dependent 
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Kinases (CDKs)58. A complete characterization of the Cyclin-CDK partners 
has been described59 (Figure 1-4), and discovery of cyclins as the regulatory 
factors driving cell cycle progression, especially in the context of mitotic 
exit, has been shown. In a landmark experiment, in vitro transcribed cyclin 
B1 mRNA added to egg extracts depleted of endogenous mRNA was 
sufficient to drive mitosis60.  
 In roughly the same timeframe, the study of proteolysis also 
broadened in scope to what we now understand to be an essential and 
equally complex system. The discovery of the lysosome as a “proteolytic 
apparatus” could only explain in part how proteins are degraded. Hydrolysis 
of peptide bonds is an ATP-dependent process and an energy requirement 
for protein degradation in prokaryotes lacking lysosomes obviated a singular 
pathway of proteolysis61. This outstanding discrepancy, together with the 
observation that lysosomal degradation is not a substrate-specific or 
temporally controlled process, prompted the search for an ATP-dependent 
system for protein degradation. This search lead to the discovery of 
ubiquitin62,63. Enzymes in the ubiquitin pathway, including E1, E2, E3, and 
de-ubiquitinating (DUBs) enzymes, and the functional connection to 
proteasomal degradation have since been characterized64–66 (Figure 1-5). The 
discovery of ubiquitin-mediated cyclin degradation67 linked these two 
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cellular processes together, and the identification of the E3 ubiquitin ligase 
known as the Anaphase Promoting Complex/Cyclosome68 laid the 
groundwork for the continued investigation of mitotic regulation, including 
the studies in this thesis. 
  
The Spindle Assembly Checkpoint and Anaphase Promoting 
Complex/Cyclosome  
 Phosphorylation events by Cdk1 regulate mitotic progression. Cdk1-
mediated phosphorylation of the nuclear lamina and components of the 
nuclear pore complex initiate prophase, benchmarked by nuclear envelope 
breakdown (NEBD) and depolymerization of the lamins69. Of note, the 
Nup358-RanGAP1-Ubc9 complex and the Nup107-160 complex both re-
localize from the nuclear pore complexes during interphase to the mitotic 
spindle and kinetochores during mitosis70,71. During mitosis, Nup358 
functions as a SUMO E3 ligase, and regulates the SUMO modification of 
Topoisomerase IIa72 at kinetochores. As chromosomes decondense, 
centromereic regions in the DNA, specified by regions containing the 
histone variant CENP-A, become recruitment centers for the Chromosome 
Passenger Complex (CPC)73. Structural proteins like Ndc80 and signaling 
kinases like Aurora B contribute to kinetochore formation and mediate 
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amphitelic microtubule attachment. Kinetochores that have not yet come 
under proper attachment with the mitotic spindle generate the Spindle 
Assembly Checkpoint (SAC)51,53 (Figure 1-6). One of the first steps in SAC 
signaling is the recruitment of Mad1 to kinetochores. Recruitment and 
conversion to the “closed” conformation of Mad2 facilitates Cdc20 capture, 
and the Mad2-Cdc20 complex can diffuse from the kinetochore to bind with 
BubR1 and Bub3 to complete the formation of the Mitotic Checkpoint 
Complex (MCC)74. The MCC binds to and inhibits the activity of the 
Anaphase Promoting Complex/Cyclosome (APC/C) (Figure 1-6). SAC 
mediated inhibition of APC/C activity is not a binary “toggle switch” but a 
“rheostat” in which timing of mitotic exit is regulated by multiple inputs so 
that chromosomes segregate equally and genome integrity is maintained75.  
 Generally, when sister chromosomes have appropriately aligned along 
the metaphase plate and kinetochores have come under proper bi-orientation 
and tension with the mitotic spindle, dynein motor proteins “strip” the 
checkpoint signal from kinetochores, effectively “silencing” the 
checkpoint76–78 (Figure 1-6). Interestingly, landmark laser ablation studies 
whereby a single microtubule was detached from a kinetochore proved to be 
sufficient to relaunch robust checkpoint signaling and inhibit anaphase 
onset79. Precisely how the SAC signal can be rapidly and robustly generated 
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is yet a mystery. Subsequent activation of the APC/C towards Cyclin B1 and 
securin are the final steps leading to mitotic exit (Figure 1-6). The APC/C is 
a RING (Really Interesting New Gene) family E3 ubiquitin ligase and is a 
multi-subunit molecular machine that facilitates the ubiquitylation of several 
mitotic substrates50. Ubiquitylation and subsequent degradation of Cyclin B1 
inactivates the mitotic Cdk1 kinase, while securin degradation results in the 
activation of separase, an enzyme that cleaves the cohesin ring holding sister 
chromosomes together54. The premature degradation of Cyclin B1 and 
securin may result in precocious mitotic exit. Thus, the APC/C must be 
carefully regulated to prevent premature sister chromosome segregation.  
 As a RING E3, the APC/C catalyzes the direct transfer of ubiquitin 
from the E2~Ub thiolester intermediate to generate a stable isopeptide 
linkage between the substrate lysine and the C-terminus of ubiquitin80 
(Figure 1-4). To date, two ubiquitin E2 enzymes have been characterized, 
including UbcH10, which binds to the cullin-like WHB (winged helix 
binding) and RING domains on the catalytic module of the APC/C, 
comprised of the APC2 and APC11 subunits, respectively81,82. Ube2S was 
identified as a chain elongating enzyme83 of the APC/C, and has since been 
shown to generate branched ubiquitin chains for efficient targeting to the 
proteasome following E3-mediated transfer84–87. Appropriate localization of 
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the APC/C at kinetochores has also been an important regulatory role for 
efficient APC/C activity and mitotic exit88–91. Whether UbcH10 and Ube2S 
localization at kinetochores is an important determinant of ubiquitin transfer 
is unknown.  
 Analysis of MCC-bound APC/C92,93 compared to substrate-bound 
structures demonstrates that the APC/C has conformational flexibility, 
especially in the APC2/11 catalytic module. Whether MCC release 
contributes to this structural change or if the APC/C is post-translationally 
modified to adopt a more stable conformation, as in the case of the 
ubiquitin-like modification of NEDD8 on the RING E3 ligase Rbx194, is yet 
unknown. Furthermore, the mechanism of release of the inhibitory MCC 
from the APC/C is still an outstanding question, while the requirement of 
APC15 subunit and the activity of AAA-ATPases have been implicated in 
this process95,96.  
 Phosphorylation of the APC/C complex has been known to be an 
important regulatory factor97, and the recruitment of coactivators, including 
Cdc20 and Cdh1, to the complex has also been known to be critical for 
activity98. Recent structural studies from three independent groups have 
detailed a molecular mechanism for how coactivator recruitment is regulated 
by mitotic phosphorylation. Phosphorylation of the APC1 subunit by Cdk1 
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relieves an autoinhibitory loop, allowing subsequent binding of the 
coactivator Cdc20 through its C-terminal IR (isoleucine, asparagine) tail 
domain and results in APC/C activity towards select substrates99–101. An 
additional coactivator, Cdh1 associates with the APC/C and is also known to 
selectively ubiquitylate late mitotic substrates102,103. However, how the 
switch from Cdc20 to Cdh1 occurs is yet an outstanding question. Finally, 
the recruitment of substrates to the APC/C is an area of particular interest, as 
selection is mediated by short linear sequence motifs, or degron motifs104. 
Notable degrons recognized by the APC/C are KEN boxes, D boxes, the 
ABBA motif, and a CRY motif104. Whether the degrons themselves 
contribute towards ordered substrate turnover or if other mechanisms 
coordinate degron recognition will provide add addition insights towards 




 Since the discovery of SUMO, a variety of SUMO substrates have 
been characterized as important regulators of mitosis (Table 2). Previous 
work in S. cerevisiae demonstrated that smt-3 and ubc-9 mutants arrest in 
mitosis, resulting in a large budded phenotype and failed to properly degrade 
the APC/C substrates Clb-3 and Pds1, homologs of human Cyclin B1 and 
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securin104. Chapter 2 describes a novel molecular mechanism of how SUMO 
modification is also required for stimulating the activity of the APC/C and 
timely degradation of CyclinB1 and securin in human cells. A follow up to a 
previously characterized requirement of SENP1 activity in regulating the 
metaphase-anaphase transition30 is presented in Chapter 3. Inquiry on the 
basic principles governing cell cycle progression have important 
implications for developing cancer therapeutics, as all of the current first line 
chemotherapies target rapidly dividing cells. A comprehensive 
understanding of how the SUMO pathway regulates mitotic progression 
provides a tractable approach towards the future development of treatment. 
 




Human SUMO Paralogs & Post-Translational Modifications of SUMO 
 Three functional SUMO isoforms are expressed in human cells, 
including SUMO1, SUMO2, and SUMO3. SUMO2 and SUMO3 share 
~96% sequence homology, and are collectively referred as SUMO2/3. 
Current techniques cannot distinguish between the SUMO2 and SUMO3. 
SUMO1 shares ~45% sequence homology with SUMO2/3. All SUMO 
paralogs can be post-translationally modified by phosphorylation, 
ubiquitylation, acetylation, and SUMO2/3 contain  












The SUMO Pathway 
 The Small Ubiquitin-related Modifier (SUMO) is first processed by 
SUMO isopeptidases (SENPs) to expose a C-terminal di-glycine motif. 
SUMO modification generally occurs at consensus site sequences, beginning 
with a hydrophobic amino acid (j), conjugation at lysine (K), followed by 
any amino acid (x), and either glutamic or aspartic acid (E/D). Covalent 
SUMO conjugation occurs through an enzymatic cascade involving E1, E2, 
and E3 enzymes. Functionally, SUMO modification results in the generation 
of novel non-covalent protein-protein interactions through recognition of a 
SUMO Interacting Motif (SIM); interactions with other post-translational 
modifications, such as ubiquitylation and subsequent substrate degradation; 
and localization of proteins to distinct sub-cellular compartments. SUMO 



















Structure of SUMO Interacting Motif (SIM) in Rap80 with SUMO2 
Non-covalent interactions between SUMO-modified proteins and proteins 
containing SUMO Interacting Motifs (SIMs) occur between amino acid 
residues Q35 (glutamine), F36 (phenylalanine), and I38 (isoleucine) of 
SUMO2 and proteins containing a hydrophobic SIM consensus sequence 
V/I-V/-x-V/I (V is valine, I is isoleucine, x is any amino acid). Rap80 








The Cell Cycle is Regulated by Cyclin/CDKs 
 Cyclins and Cyclin Dependent Kinsases (CDKs) regulate progression 
through the cell cycle. During the G1 phase of the cell cycle, Cyclin E 
interacts with CDK2, Cyclin A interacts with CDK1 and CDK2 between S 
and G2 phases, while Cyclin B interacts with CDK1 during M phase 
(mitosis). Cyclin expression increases at the beginning of each phase of the 











The Ubiquitin-Proteasome Pathway 
 Ubiquitin is a post-translational modification that is covalently added 
to substrates through the sequential activity of E1, E2, and E3 enzymes. 
Modification occurs at lysine residues, and can be reversibly removed by the 
activity of de-ubiquitinating enzymes (DUBs). Poly-ubiquitin chains target 
substrates to the 26S proteasome, whereby proteins are degraded so that 









Mitosis is Regulated by the Spindle Assembly Checkpoint and the 
Anaphase Promoting Complex/Cyclosome (APC/C) 
 At the onset of mitosis, kinetochores that have yet aligned with the 
mitotic spindle generate an inhibitory signal, known as the Spindle 
Assembly Checkpoint. Checkpoint signaling contributes to the formation 
and assembly of the Mitotic Checkpoint Complex (MCC), which binds to an 
inhibits the activity of the Anaphase Promoting Complex/Cyclosome 
(APC/C). The APC/C is a multi-subunit complex that functions as an E3 
ubiquitin ligase. Throughout mitosis, the APC/C ubiquitylates specific 
substrates. Importantly, the substrates Cyclin B1 and Securin are 
ubiquitylated during the metaphase-anaphase transition. The APC2 and 
APC11 subunits are the cullin and RING domains of the APC/C and 
function as the catalytic arm of this ligase. APC4 is a subunit described in 
this thesis that is SUMO-modified during mitosis. Depending on whether the 
MCC or a substrate is bound to the APC/C, Cryo-EM images show that the 
APC2/11 module adopts different conformations, which may be an 








SUMO Pathway Enzymes 
 
SUMO paralogs SUMO1, SUMO2, and SUMO 3 are covalently conjugated 
to substrates through the activity of activating E1, conjugating E2, and 
ligating E3 enzymes, and reversibly removed by the activity of SUMO 
Isopeptidases. 
Enzyme Vertebrate S. cerevisiae 
SUMO Paralogs 
SUMO1 Smt3 




+ Uba2/SAE2 Aos1+Uba2 
Conjugating 
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SUMOYLATION PROMOTES OPTIMAL APC/C 













The Anaphase Promoting Complex/Cyclosome (APC/C) is a ubiquitin 
ligase that functions as the gatekeeper to mitotic exit. Steps critical for 
APC/C activation have been identified, including silencing of the spindle 
assembly checkpoint. Factors that modulate APC/C following activation, 
however, remain poorly understood. We have identified a role for the small 
ubiquitin-related modifier (SUMO) in fine-tuning APC/C activity 
downstream of checkpoint silencing. Sumoylation of the APC4 subunit of 
APC/C, which peaks at the metaphase-anaphase transition, controls the 
timing of anaphase onset by enhancing APC/C activity. We have also 
identified a functionally important SUMO interacting motif in the cullin-
homology domain of APC2, a domain in the APC/C catalytic core critical 
for E2 binding. We propose that interactions between APC2 and sumoylated 
APC4 stabilize a conformation of the catalytic core that is optimized for E2 
recruitment and substrate ubiquitylation. Our findings reveal a novel 












 Aberrations during cell division can result in abnormal chromosome 
number or aneuploidy, a key hallmark of human cancers1. Cellular 
mechanisms therefore exist to safeguard against chromosome 
missegregation, including the spindle assembly checkpoint (SAC) that 
functions during the mitotic stage of the cell cycle. At the onset of mitosis, 
mitotic kinases and microtubule motor proteins coordinate attachment of 
spindle microtubules to kinetochores to appropriately align sister chromatids 
at the metaphase plate2. The SAC monitors unattached kinetochores or 
kinetochores that have not yet developed proper tension, and produces an 
inhibitory signal known as the Mitotic Checkpoint Complex (MCC)3,4. The 
MCC is composed of BubR1, Bub3, Cdc20, and Mad2 and functions to 
inhibit the activity of the Anaphase Promoting Complex or Cyclosome 
(APC/C), a ubiquitin RING E3 ligase5. Upon appropriate chromosome 
alignment, SAC silencing, and activation of the APC/C, the processive 
ubiquitylation and subsequent degradation of Cyclin B1 and securin 
promotes anaphase onset6. The dynamics between SAC signaling and 
protein turnover produces a fine-tuned “rheostat”7 responsive to multiple 
signals affecting APC/C activity and mitotic exit. 
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The multi-subunit APC/C is a member in a large family of cullin-
RING E3 ligases and functions most prominently as the gatekeeper to 
mitotic exit. APC/C activity must be exquisitely regulated to target specific 
substrates for ubiquitin-mediated proteolysis during different points in the 
cell cycle8. In part, this is coordinated by co-activator binding9, appropriate 
sub-cellular localization10–12, and SAC signaling4 during mitosis. Studies of 
APC/C structure13–15, interactions with the E2 enzymes UbcH10 and 
Ube2S16,17, and binding to degron motifs identified in substrates18 are 
beginning to provide detailed molecular insights into APC/C function and 
regulation. These findings reveal that APC/C is composed of a highly 
dynamic catalytic core including APC2, the cullin subunit, and APC11 that 
contains the RING domain. The APC2-11 module must be stabilized in 
varying conformations to allow for co-activator, E2 enzyme, and selective 
substrate binding, all culminating in APC/C activation. Phosphorylation 
provides one molecular mechanism for fine-tuning the structure of the 
APC/C catalytic core and promoting co-activator binding and activation19–22. 
Here we have identified a second post-translational modification, the 
attachment of the small ubiquitin related modifier (SUMO), as a critical 
mechanism for regulating APC/C activity in mitosis. 
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 SUMO regulates a variety of essential cellular processes, including 
DNA replication and repair, chromatin remodeling, and mitosis23. There are 
several paralogs of SUMO, including SUMO1, SUMO2 and SUMO3 with 
potentially distinct functions. SUMO2 and SUMO3 are ~96% identical and 
are collectively referred to as SUMO2/3, whereas SUMO1 is ~45% identical 
to SUMO2 and SUMO3. Analogous to the ubiquitin pathway, SUMOs are 
added to proteins by the sequential cascade of E1, E2, and E3 enzymes. 
However, the catalog of SUMO pathway enzymes in vertebrates is smaller 
in comparison to the ubiquitin system, with a single activating E1 (expressed 
as the homodimer Aos1/Uba2), a single E2 conjugating enzyme (Ubc9) and 
approximately a dozen E3 ligases24. The SUMO pathway also includes a 
family of cysteine proteases, known as Sentrin Isopeptidases (SENPs), that 
reversibly remove SUMOs from substrates25. Regulation at the level of 
deconjugation is an important axis controlling SUMO function, as 
demonstrated by the importance of SENP1 and SENP2 in regulating mitotic 
progression26. Although dynamic cycling between conjugation and de-
conjugation can result in a relatively low steady-state level of sumoylation 
for many substrates, sumoylation nonetheless produces profound effects on 
substrate localization and function in a variety of cellular pathways.   
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 One functional paradigm for SUMO is that it acts as “molecular 
Velcro” to generate non-covalent interactions between proteins and facilitate 
protein complex assembly27. Novel protein-protein interactions are generated 
between sumoylated proteins and proteins containing SUMO-interacting 
motifs (SIMs). SUMO-SIM interactions are required for the assembly of 
complex cellular structures, including PML nuclear bodies28, ribosomes29 
and kinetochores28,30–32. Early genetic studies in S. cerevisiae have also 
identified SUMO pathway components as essential for progression through 
mitosis33–35. Yeast sumoylation mutants result in a large budded phenotype 
and fail to properly degrade APC/C substrates Pds1 and Clb-3, indicating an 
essential role for sumoylation during the metaphase-anaphase transition36. 
Precisely how sumoylation regulates the metaphase-anaphase transition in 
higher order eukaryotes has not yet been defined. Additional investigations 
in human cell lines have underscored the importance of sumoylation in early 
mitotic processes, including kinetochore-microtubule interactions30,37, sister 
chromatid cohesion38,39, and checkpoint signaling40–42. Recent proteomic 
studies have also identified sumoylation sites on subunits of the APC/C, 
suggesting novel roles for sumoylation during the metaphase-anaphase 
transition43–46.  
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Here, we demonstrate that the APC/C subunit APC4 is sumoylated at 
two C-terminal residues. We show that APC4 sumoylation peaks at the 
metaphase-anaphase transition, enhances APC/C activity, and is required for 
normal anaphase onset. In addition, our findings demonstrate that the cullin-
containing APC/C subunit, APC2, also contains a functional C-terminal 
SIM, which is in close spatial proximity to APC4 sumoylation sites. Our 
data show that the SUMO-SIM interaction between APC4 and APC2 is 
required for normal anaphase onset. We propose that interactions between 
SUMO-modified APC4 and the SIM in APC2 stabilize a conformation of 




MATERIALS AND METHODS 
 
Plasmids and cell lines 
The coding sequence for APC4 was PCR-amplified from pENTR221 
ANAPC4 (Ultimate Human ORF Collection, HiT Center, Johns Hopkins 
University) and subcloned into pJET 1.2 (ThermoFisher Scientific). The 
linear SUMO2 fusion (without the C-terminal di-glycine) was PCR-
amplified and inserted in frame to the C-terminus of APC4 in the vector 
above.  APC2 was sub-cloned into the pCITE vector from a plasmid (a gift 
from Hongtao Yu, UT Southwestern). Single N-terminal FLAG tags were 
inserted using PCR-amplified sequences. Single (APC4K772A, APC4K798A), 
double (APC4K772/798A, APC4K772/798R, APC2SIM Mutant), and triple mutants 
(APC4KRSUMO2QFI) were generated by PCR-based QuickChange site-
directed mutagenesis (Stratagene, La Jolla, CA) using the wild-type APC4, 
APC2, and SUMO2 vectors as a template.  
293FT and YFP-H2B HeLa cells (a gift from Andrew Holland, Johns 
Hopkins University, Baltimore, MD) were used to generate tetracycline-
inducible cell lines. Lentiviruses containing a blasticidin-resistant 
tetracycline inducible plasmid, in addition to hygromycin-resistant APC4 or 
APC2 transgenes were incorporated via lentiviral infection as described 
previously47,48. In brief, 1 µg of lentiviral DNA construct, 800 ng psPAX2 
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(Addgene, Cambridge, MA, USA), and 200 ng pMD2.G (Addgene) were 
transfected into 293FT cells using XTremeGene HP (Roche) according to 
manufacturer’s instructions. After 48 h, the viral supernatant was filtered 
through a 0.44 µM PVDF membrane and transduced to YFP-H2B HeLa 
cells in the presence of 8 µg/mL polybrene (Santa Cruz Biotechnology). 
After 24 h, cells were treated with 10 µg/mL blasticidin to select for the 
tetracycline-inducible cells for 1 week. Selection for stable cell lines was 
performed with hygromycin B (Roche) at a final concentration of 200 
µg/mL for an additional week concomitant with 10 µg/mL blasticidin 
selection. Individual blasticidin and hygromycin-resistant colonies were 
isolated with cloning discs (after ~2 weeks) and tested for APC4 or APC2 
expression by immunoblot analysis.  
 
Cell culture and synchronization 
293FT, JW36 HeLa, YFP-H2B HeLa, U2OS, and 6xHis-SUMO2 (a 
gift from Mary Dasso, National Institutes of Health, Bethesda, MD) cells 
were maintained at 37°C in a 5% CO2 atmosphere. Cells were grown in 
DMEM medium (Gibco) containing 10% fetal bovine serum (Atlanta 
Biologicals). Thymidine (Sigma-Aldrich) was dissolved in DMSO and used 
at a final concentration of 2 mM. Nocodazole (Calbiochem) was dissolved in 
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DMSO and used at a final concentration of 100 ng/mL or 3.3 µM as 
indicated. To synchronize cells into S phase, cells were cultured in the 
presence of 2 mM thymidine for 19 h, released in drug-free media for 6 h, 
and cultured in 2 mM thymidine for 19 h. For mitotic timecourse analysis, 
cells were released from the double thymidine block and harvested in 2x 
SDS-sample buffer at indicated timepoints.  
To weaken SAC signaling, 50 nM of the Mps1 kinase inhibitor, 
Reversine (Cayman Chemical, Ann Arbor, Michigan), was used 
immediately before timelapse acquisition. 
 
RNAi interference 
JW36 HeLa or YFP-H2B HeLa cells were transfected using 
Lipofectamine RNAiMAX (Invitrogen) and siRNA oligonucleotides at a 
final concentration of 20 nM for 48 hours and before analysis by 
immunoblotting, timelapse microscopy, or immunofluorescence microscopy. 
Stable cell lines were treated with doxycycline to induce expression of 
FLAG-APC4, FLAG-APC4KR, or FLAG-APC4KR-SUMO-2 concomitant 
with siRNA depletion of endogenous APC4. Two oligonucleotides targeting 
the 3’ UTR of APC4 were validated, but oligonucleotide 2 was used for all 
experiments. APC4 oligonucleotides were purchased from Dharmacon:  
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APC4 Oligo 1: (5’ – AGCUUGCCAUUAUUGUGUGUGUAAU – 3’),  
APC4 Oligo 2: (5’ – CAUAGGAGAUGGACUAAGAUGUCUUGG – 3’);  
Scramble control: (5’ –CUUCCUCUCUUUCUCUCCCUUGUGA-3’), and  
SENP1 oligo(b): (5’ GCAAAUGGCCAAUGGAGAAAUUCUA-3’) and  
SENP2 oligo(a): (5’AUAUCUGGAUUCUAUGGGAUU-3’) were used as 
previously described26.  
 APC2 oligonucleotides were designed using the BLOCK-iT RNAi 
Designer (ThermoFisher Scientific) to target the 5’ UTR and purchased from 
Integrated DNA Technologies: 5’ – 
TGGCTGCGCGTGCAGACGTGCGTCA – 3’. 
 
In Vitro Sumoylation 
APC4 wild-type, APC4K772A, APC4K798A, APC4K772/798A, and 
RanGAP1 were produced by in vitro transcription and translation in rabbit 
reticulocyte lysate in the presence of [35S]methionine according to the 
manufacturer’s instructions (Promega, Madison, WI). 2 µL of translation 
product was added to a 30 µL reaction containing 200 nM human SUMO E1 
enzyme, 600 nM human Ubc9, 1.0 µM human SUMO-1 or SUMO-2 
proteins, 1 mM ATP, 20 units/mL creatine phosphokinase, 5 mM 
phosphocreatine, 0.6 µg/ml inorganic pyrophosphatase from E. coli, 20 mM 
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HEPES-KOH (pH 7.3), 110 mM potassium acetate, 2 mM magnesium 
acetate, and 1 mM dithiothreitol (DTT). Reactions were incubated at 30°C 
for the indicated times and stopped by addition of 2x SDS-sample buffer and 
analyzed by SDS-PAGE followed by autoradiography. 
 Recombinant SUMO proteins and SUMO enzymes were purified 
from E. coli as previously described (Yunus and Lima, 2009).  
 
Antibody and imaging techniques 
For immunoblotting, proteins were separated by SDS-PAGE, 
transferred onto nitrocellulose membranes, blocked in 5% milk in TS-T, and 
then probed with the following antibodies diluted in PBS supplemented with 
2% BSA and 0.05% NaN3: APC2 (rabbit, 1:1000 a generous gift from 
Hongtao Yu), APC4 (rabbit, A301-176A, 1:2000, Bethyl Laboratories, Inc), 
BubR1 (rabbit, GeneTex, 1:1000) Cyclin B1 (mouse, GNS1: sc-245, 1:200, 
Santa Cruz Laboratories), Cdc20 (mouse, p55 CDC (E-7): sc-13-162, 1:250, 
Santa Cruz Laboratories), ECS (DDDDK, goat, 1:1000, A190-101A, Bethyl 
Laboratories, Inc.), GAPDH (rabbit, TAB1001, OpenBiosystems, 1:15,000), 
Myc (mouse, a generous gift from Hongtao Yu), SENP1 (rabbit, ab108981, 
1:10,000, Abcam), SENP2 (rabbit polyclonal, produced as described 
previously: Goeres et al., 2011, 1:500), SUMO-1 (21C7, 1:100), SUMO-2/3 
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(8A2, 1:800), and Tubulin (mouse, DM1A, 1:5000, Sigma-Aldrich.) 
Secondary antibodies conjugated to HRP (Jackson Laboratories) were used 
at 1:10,000 diluted in 5% milk in TS-T. Immunoblot analysis was performed 
using either an enzyme-linked chemiluminescent substrate (Luminata 
Crescendo Western HRP Substrate, EMD Millipore) and developed with 
film or IR Dye-labeled secondary antibodies (anti rabbit IgG IRDye 800, LI-
COR 926-32211) and imaged using the Odyssey infrared imager (LI-COR). 
Images were processed with Adobe Photoshop CS6. 
To test the localization of Flag-APC4 and Flag-APC4KR, cells were 
depleted of endogenous APC4 using siRNA and induced with doxycycline 
for 48 hours on glass coverslips. Cells were permeabilized using transport 
buffer (200 mM HEPES pH 6.5, 110 mM potassium acetate, 20 mM 
magnesium acetate, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 20 µg/mL 
aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 20 mM N-
ethylmaleimide (NEM), and 20 µg/mL digitonin) at room temperature for 15 
min. Cells were then washed 1x with PBS, and fixed in 2% formaldehyde at 
room temperature for 20 mins. After washing with PBS, cells were 
immunostained at room temperature using respective antibodies. 
 For SAC co-localization studies using immunofluorescence 
microscopy, stable cell lines were induced with doxycycline to express 
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FLAG-APC4 or FLAG-APC4KR with siRNA against APC4 for 48 hours on 
glass coverslips. Cells were fixed in 3.5% paraformaldehyde in PBS for 7 
min and permeabilized in 0.5% Triton-X 100 in PBS for 20 min at room 
temperature. Immunostaining was performed with the following antibodies 
diluted in PBS supplemented with 2% BSA: BubR1 (rabbit, GeneTex, 
1:500), Cdc20 (mouse, p55 CDC(E-7): sc13-162, 1:50), CREST (human, 
15-235-0001, Antibodies Inc., 1:100), FLAG (mouse, M2, 1:300, Sigma-
Aldrich), Mad1 (mouse, 1:500, Active Motif), and Mad2 (rabbit, Covance, 
1:500), followed by secondary antibodies to Alexa Fluor 594 and Alexa 
Fluor 647 at (1:300, Life Technologies, Grand Island, NY). Images were 
acquired using a Zeiss Observer Z1 fluorescence microscope with a Zeiss 
Plan-Apochromat 63x objective (numerical aperture 1.40) and Apotome VH 
optical sectioning grid (Carl Zeiss, Jena, Germany). Images were obtained at 
room temperature with immersion oil using a Zeiss AxioCam MRm camera 
and processed using AxioVision Software Release 4.8.2 and Adobe 
Photoshop CS6. 
For immunoprecipitations to detect SUMO-modified APC4, lysates of 
YFP-H2B HeLa cells were treated with siRNA oligonucleotides against 
endogenous APC4 and induced with doxycycline for FLAG-APC4 or 
FLAG-APC4KR expression for 48 h. Cell lysates were arrested in 
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prometaphase with a 3.3 µM nocodazole treatment for 4 hours and harvested 
in RIPA lysis buffer supplemented with protease inhibitors (cOmplete 
ULTRA EDTA-free tablets, Roche), 1mM phenylmethylsulfonyl fluoride 
(PMSF), and 10 mM N-ethylmaleimide, sonicated, and centrifuged 14,000 
rpm for 20 min at 4°C. Protein lysates were quantified using a bicinchoninic 
acid protocol (ThermoScientific) to normalize protein inputs. Cell lysates 
were incubated with rabbit anti-APC4 antibodies (rabbit, 2 µg antibody per 
mg of cell lysate, Bethyl Laboratories) immobilized on Protein-A agarose 
beads (sc-2001, Santa Cruz) and incubated at 4°C overnight. Beads were 
washed with RIPA buffer 3x and proteins were eluted directly in 2x SDS-
sample buffer. 
 
Ni-NTA Affinity Purification 
 To investigate APC4 sumoylation during mitosis, U2OS or 6xHis-
SUMO2 U2OS cells were synchronized into S phase using 2 mM thymidine 
or treated with 100 ng/mL nocodazole for 16 hours for prometaphase arrest, 
followed by 2, 4, or 8 hours release into drug-free media. Cells were washed 
1x in PBS and flash frozen in liquid nitrogen until assays were performed. 
Cells were lysed in 6 M guanidine HCl lysis buffer, containing: 6 M 
guanidine HCl, 100 mM NaCl, 10 mM imidazole, 10 mM Tris-HCl pH 8.5, 
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and 10 mM b-Mercaptoethanol. Cells were sonicated briefly, cleared by 
centrifugation, and incubated with pre-washed Ni-NTA agarose (QIAGEN) 
for 2 hrs at 4°C. After a series of wash steps (1x Buffer A: 6M guanidine 
HCl, 10 mM Tris-HCl pH 8.5, 300 mM NaCl, 20 mM imidazole, 1% TNX-
100, 1x Buffer B: 8M urea, 10 mM Tris-HCl pH 8.5, 300 mM NaCl, 20 mM 
imidazole, 1% TNX-100, 2x Buffer C: 8M urea, 10 mM Tris-HCl pH 6.5, 
300 mM NaCl, 20 mM imidazole, 1% TNX-100), proteins were eluted in 2x 
SDS-sample buffer and analyzed by SDS-PAGE and immunoblotting.  
 
APC/C ubiquitination assays 
For APC/C activity assays, cells were treated with doxycycline to 
induce APC4 or APC2 expression for 24 hours, synchronized into S phase 
using 2 mM thymidine in the presence of doxycycline, released into drug-
free media for 6 hours, and arrested in prometaphase using 100 ng/mL 
nocodazole for 5 hours. Cell pellets were washed 1x with PBS and flash 
frozen in liquid nitrogen. Ubiquitylation reactions were performed as 
previously described (Ji et al. 2017). Briefly, cells were lysed using a 25G 
5/8 needle (BD PrecisionGlide) in 50 mM HEPES pH 7.5, 120 mM KCl, 
3mM MgCl2, 0.1% NP-40, protease inhibitors (cOmplete ULTRA EDTA-
free tables, Roche), phosphatase inhibitors (PhosSTOP, Sigma-Aldrich), 1 
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mM DTT, and turbonuclease (Sigma-Aldrich, T4330-50KU). Cleared 
lysates (from a 30 min spin at 14,000 rpm and 4°C) were incubated with 
anti-goat DDDDK-conjugated agarose beads (ECS, S190-101, Bethyl 
Laboratories) for 2 hours. After wash 2x with detergent-free buffer (10 mM 
HEPES, pH 7.5, 100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2) proteins were 
eluted directly in 2x SDS-sample buffer and analyzed by SDS-PAGE and 
immunoblotting for APC2. Remaining fractions of beads were incubated 
with 1 µg recombinant human Cdc20 (a generous gift from Hongtao Yu) for 
1 h, followed by an in vitro ubiquitylation reaction buffer (10 mM HEPES, 
pH 7.5, 100 mM KCl, 0.1 mM CaCl2, 1 mM MgCl2) including 150 µM 
bovine ubiquitin (Sigma), 5 µM Uba1, 750 nM UbcH10, 3 µM Ube2S, and 
5µM Myc-tagged Cyclin B1, supplemented with 1X energy mixture (7.5 
mM phosphocreatine, 1 mM ATP, 100 µM EGTA, and 1 mM MgCl2). After 
incubation at room temperature with gentle shaking for 15, 30, or 60 min, 




For live-cell imaging, cells were cultured in Lab-Tek Chambered #1.0 
Borosilicate Coverglass slides (Nunc, Rochester, NY), doxycycline induced 
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and siRNA treated targeting APC4, and then imaged 48 hours post-
transfection. Immediately before imaging, cells were switched to pre-
warmed CO2-independent media (Invitrogen) supplemented with 10% FBS. 
Cells were maintained at 37°C on a Zeiss Observer Z1 fluorescence 
microscope fitted with an incubation chamber. Images were acquired using a 
Zeiss EC Plan-Neofluar 40x objective (numerical aperture 1.3) every 5 min 
for 16 hours with a Zeiss AxioCam MRm camera and processed using 
AxioVision Software Release 4.8.2. Data analysis was performed using 
Prism 6 for Mac OS X (GraphPad Software, Inc.) 
 
Statistical analysis 
Statistical analyses were carried out using Prism 6 for Mac OSX 
(GraphPad Software, Inc.) with two-tailed student t tests. Data with a P-










APC4 is sumoylated in a cell-cycle dependent manner at lysines 772 and 
798 
 APC4 is a protein subunit at the base of the APC/C that is sumoylated 
in mitosis46. To more precisely characterize the temporal regulation of APC4 
sumoylation during the cell cycle, we synchronized HeLa cells using a 
double thymidine block. After release from thymidine for varying lengths of 
time, cell lysates were analyzed by immunoblotting for APC4 and the 
APC/C substrates, Cyclin B1 and Cdc20 (Figure 1A). Consistent with a 
possible role in regulating APC/C activity in mitosis, APC4 sumoylation 
levels (evidenced by the detection of a predominant high molecular mass 
protein band migrating at 120 kDa) increased with entry into mitosis and 
peaked at the time of Cyclin B1 degradation. To further demonstrate that 
APC4 is sumoylated in a mitosis-dependent manner, we utilized a stably 
expressing 6xHis-SUMO2 U2OS cell line and a parent U2OS cell line as a 
control. Cells were synchronized at different stages of the cell cycle and 
SUMO-modified proteins were captured using Nickel-NTA agarose. 
Affinity purifications from both U2OS and 6xHis-SUMO2 U2OS cells 
capture the unmodified form of APC4, which migrates at ~97 kDa. 
Immunoblots confirm that APC4 is SUMO-modified based on the 
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appearance of a shift in molecular weight at ~120 kDa in nocodazole-
arrested 6xHis-SUMO2 U2OS cells that does not appear in the U2OS cell 
line (Sup. Figure 1A). APC4 sumoylation levels peak at mitotic entry 
followed by a subsequent decrease during mitotic exit (Sup. Figure 1A).  
 Human APC4 contains two C-terminal lysine residues located within 
consensus sumoylation sites, at positions 772 and 798, that have previously 
been reported to be sumoylated in high throughput mass spectrometry 
studies43–46 (Figure 1B). To characterize APC4 sumoylation and 
modification at K772 and K798, we expressed wild type and mutant variants 
of APC4 in rabbit reticulocyte lysate in the presence of [35S]-methionine. 
Translation products were incubated in reactions containing recombinant 
SUMO E1 activating and E2 conjugating enzymes and SUMO2 for varying 
lengths of time and analyzed by SDS-PAGE and autoradiography (Figure 
1C). In reactions containing wild type APC4, we observed two prominent 
high molecular mass bands of 120 and 135 kDa, consistent with sumoylation 
at two sites. In reactions containing APC4 with single amino acid 
substitutions at either K772A or K798A, a single high molecular mass band 
of 120 kDa was observed, whereas sumoylation was abolished in reactions 
containing the K772A/798A double mutant. Reactions were also performed 
in the presence of recombinant SUMO1 with comparable results but with 
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lower efficiency compared to SUMO2 (Sup. Figure 1A). In vitro reactions 
demonstrate that lysine 798 is more efficiently modified by either SUMO1 
or SUMO2, suggesting a functionally important role for the C-terminal 
lysine (Figure 1C and Sup. Figure 1B). Thus, our findings are consistent 
with previous mass spectrometry studies indicating that APC4 is sumoylated 
at two C-terminal lysine residues at positions 772 and 798. 
 To verify that K772 and K798 are the major sites in APC4 sumoylated 
in vivo, we generated stable HeLa cell lines allowing for inducible 
expression of FLAG-tagged, wild type APC4 (APC4) or a K772/798R 
mutant, hereafter referred to as APC4KR (Figure 1D). These cells also 
constitutively expressed yellow fluorescent protein (YFP)-tagged histone 
H2B to facilitate live cell imaging. To investigate APC4 sumoylation using 
these cell lines, we depleted endogenous APC4 using siRNAs directed 
against the 3’ UTR and induced expression of the FLAG-tagged transgenes 
to near endogenous levels (Figure 1E). APC4 was immunoprecipitated from 
cell lysates using FLAG-specific antibodies and immunoblotting analysis 
was performed using APC4- or SUMO2/3-specific antibodies. Two 
SUMO2/3-modified protein bands were detected at 120 and 135 kDa in 
immunoprecipitates from wild type cells (Figure 1F), but not in 
immunoprecipitates from cells expressing APC4KR (Figure 1G). We also 
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evaluated sumoylation by SUMO1 with comparable results (Sup. Figure 
1C). These findings confirm that K772 and K798 are the major APC4 
sumoylation sites in vivo. 
We also explored the regulation of APC4 sumoylation by SUMO 
isopeptidases by depleting cells of SENP1 or SENP2, two isopeptidases 
critical for normal mitotic progression26 (Cubeñas-Potts et al. 2013). SENP1 
or SENP2 were depleted using siRNAs as previously described26, and cells 
were synchronized at metaphase using a nocodazole block followed by a 2-
hour release into media containing the proteasome inhibitor MG13249. 
Immunoblot analysis of cell lysates revealed that APC4 sumoylation is 
specifically enhanced in SENP1-depleted cells compared to control or 
SENP2-depleted cells (Sup. Figure 1D), implicating SENP1 as a regulator of 
APC4 sumoylation in mitosis.  
 
Sumoylation of APC4 is required for timely metaphase to anaphase 
transition  
 As a subunit of the APC/C, APC4 is predicted to be essential for 
normal cell cycle progression. To test this prediction, we depleted cells of 
endogenous APC4 by siRNA knockdown and analyzed cells after 48 hours 
using timelapse microscopy. This analysis revealed that ~88% of cells die as 
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a result of defects in mitosis (Figure 2A). Specifically, 20% of cells undergo 
a prolonged metaphase as defined as >60 min, and 69% undergo an 
abnormal mitosis—including defects in chromosome congression and 
inability to maintain a metaphase plate—resulting in cell death as depicted in 
single frame images (Figure 2B). These observations are consistent with 
defects observed in cells depleted of other essential APC/C subunits50. 
Having established that APC4 is an essential APC/C subunit required 
for mitotic progression, we next sought to investigate the function of APC4 
sumoylation with knockdown and rescue experiments using the inducible 
cell lines described above. Cells were depleted of endogenous APC4 by an 
siRNA targeting the 3’ UTR and concomitant induction of APC4 or APC4KR 
for 48 hours. Progression through mitosis was analyzed after 16 hours of 
timelapse acquisition beginning with nuclear envelope breakdown (NEBD) 
and ending with anaphase onset. Induction of the APC4KR mutant was not as 
effective as wild type APC4 in rescuing the APC4 knockdown defects, as 
cells exhibited a significant metaphase to anaphase delay before mitotic exit 
(Figure 2A, 2C-E). On average, APC4 cells spent 35.35 min to transition 
from NEBD-metaphase and APC4KR cells spent 37.94 min. Further analysis 
revealed that cells expressing APC4 or APC4KR do not have statistically 
significant differences (p = 0.38) in the time from NEBD to metaphase, but 
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have significant differences (p < 0.0001) in the time between metaphase and 
anaphase onset (Figure 2C-D). On average, APC4 cells spent 23.04 min 
from metaphase to anaphase and APC4KR cells spent 86.49 min. Despite the 
observed metaphase delay, APC4KR expressing cells ultimately progressed 
to anaphase and exited mitosis normally.  
Sequence homology in higher eukaryotes reveals well-conserved 
sumoylation consensus sites at lysines 772 and 798 in the C-terminus of 
APC4 (Sup. Figure 1A). To determine if individual SUMO mutants affect 
mitotic progression, we generated stable inducible cell lines with a single N-
terminal FLAG tag and lysine to arginine substitutions at either lysine 772 or 
798 (Sup. Figure 1B). Single clones were depleted of endogenous APC4 
using siRNA, and FLAG-APC4772R (APC4772R) or FLAG-APC4798R 
(APC4798R) expression was induced using doxycycline for 48 hrs prior to 
timelapse acquisition (Sup. Figure 1C). Single APC4 sumoylation mutants 
result in a metaphase-anaphase delay intermediate between APC4 wild type 
and the double APC4 sumoylation mutant (Sup. Figure 1D). These data 
suggest that both APC4 sumoylation mutants are necessary for prolonged 
metaphase delay and that a single sumoylation site is sufficient for mitotic 
exit. Furthermore, cells expressing single APC4 mutations exit mitosis 
normally without obvious chromosomal abnormalities. On average, 
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APC4772R cells and APC4K798R cells take 30 minutes and 38 minutes to 
progress from NEBD-metaphase, respectively, compared to 26 minutes in 
control cells (Sup. Figure 1E). These differences are not statistically 
significant (Control vs. APC4772R p = 0.16, Control vs. APC4798R p = 0.07). 
On average, APC4772R cells took 40 minutes to transition from metaphase-
anaphase, and APC4798R took 66 minutes. Compared to control cells, which 
spent 27 minutes in metaphase-anaphase, both APC4772R and APC4798R cells 
have statistically significant differences (p = 0.03 and p = 0.03, respectively) 
(Sup. Figure 1F). However, both single mutants partially rescue the 
prolonged delay observed in the double mutant, which comparatively spends 
an average of 86 minutes in the metaphase-anaphase transition.  
To explore the molecular basis of the metaphase to anaphase delay 
observed in APC4KR expressing cells, we monitored the degradation of the 
APC/C substrates, Cyclin B1 and Cdc20. Following depletion of 
endogenous APC4 and induction of APC4 or APC4KR, cells were 
synchronized using a double thymidine block and released in drug-free 
media. In APC4 expressing cells, APC4 sumoylation peaked concomitantly 
with declines in Cyclin B1 and Cdc20 protein levels, beginning at ~12 hours 
following thymidine release (Figure 2F). As expected, APC4 sumoylation 
was not observed in APC4KR expressing cells (Figure 2G). In addition, the 
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rate of decline in Cyclin B1 and Cdc20 protein levels was substantially 
reduced compared to wild type APC4 expressing cells. Specifically, Cyclin 
B1 levels in APC4 cells are degraded ~12 h following thymidine release, 
while APC4KR cells show comparable Cyclin B1 turnover at ~15 h following 
thymidine release (Fig. 2F-G). CyclinB1 protein levels from three 
independent experiments were normalized and quantified (Figure 2H). On 
average, the rate of CyclinB1 turnover is attenuated in APC4KR expressing 
cells. CyclinB1 levels reach 50% of peak at approximately 12 hours 
following double thymidine release in APC4 expressing cells whereas 
APC4KR expressing cells reach similar levels at ~14 hours following release 
(Figure 2H). This observation indicates that the delay in anaphase onset 
detected in APC4KR expressing cells correlates with a deficiency in the 
turnover of APC/C-dependent target proteins. Taken together, our findings 
suggest that APC4 sumoylation is required for optimal APC/C function. 
 
APC4 sumoylation does not affect APC/C or MCC localization at 
kinetochores 
 Sumoylation is known to affect protein localization, including 
targeting to kinetochores in mitosis32,51. In addition, spindle checkpoint 
signaling is important for recruiting APC/C to kinetochores, suggesting 
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localization as a critical factor affecting APC/C function10–12. To test 
whether the metaphase delay observed in APC4KR expressing cells was due 
to defects in APC/C localization, we performed immunofluorescence 
microscopy on FLAG-tagged APC4 and APC4KR expressing cells. Cells 
were co-stained with anti-FLAG and CREST (a kinetochore marker) 
antibodies.  Both APC4 and APC4KR were detected at kinetochores in 
prometaphase and metaphase cells at similar levels (Figure 3A). In addition, 
kinetochore localization dissipated similarly in wild type and APC4KR 
expressing cells upon anaphase onset (Figure 3A-B).  
We also performed immunofluorescence microscopy to investigate 
how the kinetochore recruitment and turnover of SAC proteins is affected in 
APC4KR expressing cells. Mitotic cells were analyzed using antibodies 
specific for SAC proteins including Mad1, Mad2, BubR1, and Cdc20 
(Figure 2C-F). As expected, APC4 expressing cells accumulate each of these 
SAC proteins at high levels in prometaphase and these levels decrease 
significantly at metaphase and through anaphase. Comparable results were 
obtained using APC4KR expressing cells. These findings indicate that neither 
the localization of APC/C to kinetochores nor the recruitment and release of 
MCC proteins are regulated by APC4 sumoylation. 
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APC4 sumoylation is critical downstream of spindle assembly 
checkpoint inactivation 
To directly test if APC4 sumoylation is required for APC/C activation 
independent of spindle assembly checkpoint (SAC) signaling, we weakened 
the SAC using reversine, an inhibitor of the Mps1 kinase52. APC4 and 
APC4KR cells were depleted of endogenous APC4 by siRNA and transgene 
expression was induced with doxycycline for 48 hours prior to drug 
treatment, which was administered at the start of timelapse imaging (Sup. 
Figure 3A). Progression through mitosis beginning with nuclear envelope 
breakdown (NEBD) to anaphase onset was analyzed after 4 hours of 
timelapse acquisition. On average, APC4 cells spent 48.65 minutes in 
mitosis (NEBD to anaphase onset, SD = 15.99 min) and 34.87 minutes (SD 
= 11.00 min) when treated with reversine (Sup. Fig. 3B). This difference 
was statistically significant (p = 0.0014). APC4KR cells spent 81.48 minutes 
(SD = 30.78 min) in mitosis while reversine treated APC4KR cells averaged 
78.78 minutes (SD = 21.41 min). Fixed images from timelapse microscopy 
analyses demonstrate that reversine treatment weakens checkpoint signaling 
in APC4 cells, resulting in premature anaphase and a precocious mitotic exit 
in APC4 expressing cells (Sup. Figure 3C-D) while APC4KR cells treated 
with reversine still undergo a prolonged mitosis (Sup. Figure 3E-F). This 
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difference in total mitotic timing was not statistically significant in between 
APC4KR and APC4KR cells treated with reversine (p = 0.73), supportive of a 
functional role for APC4 sumoylation downstream of checkpoint 
inactivation.  
 
SUMO fusion to APC4 bypasses the need for its sumoylation in mitotic 
progression 
Having established that a defect in APC4 sumoylation affects timely 
Cyclin B1 degradation and anaphase onset, we next sought to investigate the 
consequences of constitutive APC4 sumoylation. Towards this end, we 
generated a stable cell line allowing for inducible expression of a FLAG-
tagged linear APC4-SUMO2 fusion protein (Figure 4A). Linear SUMO 
fusions have successfully mimicked conjugation at internal lysines in 
multiple other proteins53,54. Our rationale for utilizing SUMO2 was based on 
in vitro analysis demonstrating that SUMO2 is conjugated to APC4 more 
efficiently (Fig. 1C, Sup. Fig. 1B) in addition to the finding that SUMO2/3 
plays a dominant role during mitosis compared to SUMO130. A single 
SUMO2 was fused to the APC4 K772/798A mutant protein, which allowed 
us to assess functionality, as discussed below. 
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To investigate the consequences of constitutive APC4 sumoylation, 
endogenous APC4 was depleted using siRNA knockdown and the APC4KR-
SUMO2 fusion protein (APC4KR-S2 or KR-S2) was induced to near 
endogenous expression levels (Figure 4B). Following 48 hours of siRNA 
depletion and transgene expression, cell cycle progression was analyzed by 
timelapse microscopy (Figure 4C). Time course analysis revealed no 
measurable differences between control and APC4KR-S2 expressing cells. No 
defects in the timing from NEBD to chromosome alignment at the 
metaphase plate were observed, and importantly, the timing from metaphase 
alignment to anaphase onset was normal (Figure 4D-E). On average, control 
cells took 22.83 minutes to progress from NEBD-metaphase and 27.42 
minutes from metaphase to anaphase, while APC4KR-S2 cells took 24.58 
minutes to progress from NEBD-metaphase and 25.08 minutes from 
metaphase to anaphase. Thus, fusing SUMO2 to the C-terminus of APC4KR 
rescues the requirement for sumoylation at K772 and K798, a demonstration 
of the functionality of the linear fusion protein. The absence of any overt 
consequences on cell cycle progression reveals that forced sumoylation of 
APC4 alone does not cause untimely APC/C activation. 
 
APC4 sumoylation enhances APC/C ubiquitin E3 ligase activity 
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Collectively, our findings suggest that sumoylation of APC4 may 
function downstream of spindle checkpoint inactivation to enhance APC/C 
activity and the degradation of Cyclin B1 and other target proteins. To 
directly measure the effects of APC4 sumoylation on APC/C activity, we 
performed in vitro ubiquitylation assays using APC/C complexes 
immunopurified from our stable, inducible cell lines and recombinant N-
terminal fragment of Cyclin B1 as a substrate. APC/C was immunopurified 
from FLAG-tagged APC4 and APC4KR-S2 cell lysates using anti-FLAG 
antibodies conjugated to Affi-Prep beads under conditions where 
sumoylation of the wild type protein was undetectable (Figure 4F). 
Immunoblot analysis using antibodies for APC2 demonstrated that 
equivalent levels in intact complexes were isolated under each condition 
(Figure 4G). The ubiquitylation of Cyclin B1 was monitored by immunoblot 
analysis after 15, 30, and 60 min reaction times (Figure 4H). Consistent with 
our in vivo evidence suggesting that APC4 sumoylation enhances rates of 
Cyclin B1 turnover (Figure 2F), this assay revealed that APC4KR-S2 
complexes more efficiently ubiquitylate Cyclin B1 compared to wild-type 
APC4 complexes (Figure 4H and I). Relatively modest ubiquitylation in our 
hands may be due to close proximity of FLAG-APC4 to the catalytic center 
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of the APC/C, but our assays nonetheless demonstrate the laddering typical 
of in vitro ubiquitylation reactions. 
 
APC2 contains a conserved C-terminal SIM critical for APC/C function 
 To investigate the underlying mechanism of how APC4 sumoylation 
stimulates APC/C activity, we analyzed previously published high-
resolution Cryo-EM structures of the APC/C from the Barford, Schulman, 
and Yamano groups17,19,20,55–57. While the extreme C-terminal residues of 
APC4 (residues 757-808) containing the sumoylation sites are disordered 
and not visible in these structures, the location of the visible C-terminus 
(residue 756) suggests that sumoylated APC4 residues are in close proximity 
(within ~35 Å) to the C-terminus of APC2 (Figure 5A). Notably, APC2 is 
part of the structurally dynamic catalytic core of APC/C and critical for E2 
binding and positioning56,57. Sequence analysis of APC2 revealed a potential 
SIM in the C-terminus that is conserved across mammals (Figure 5B, 6A). 
The SIM consists of a stretch of hydrophobic residues followed by 
negatively charged aspartic acid residues from 727-738, just prior to the 
winged helix B domain that is critical for APC/C activity57,58. 
 To determine whether this predicted SIM mediates interactions 
between APC2 and SUMO, we expressed wild type APC2 and a SIM 
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mutant, containing alanine substitutions at residues 728 and 729 (Figure 5B), 
in rabbit reticulocyte lysate supplemented with [35S]-methionine. Translated 
proteins were pulled down with immobilized recombinant GST or a 
recombinant GST-SUMO fusion protein (GST-SUMO2x3), and binding was 
evaluated by SDS-PAGE and autoradiography as well as scintillation 
counting. This analysis revealed specific interactions between APC2 and 
SUMO2 that was dependent on the predicted C-terminal SIM (Figures 5C-
E). Binding assays performed using deletion mutants verified the presence of 
this single functional SIM in the C-terminus of APC2 (Sup. Figure A-D).  
 Based on its predicted proximity to sumoylated APC4 residues, we 
hypothesized that non-covalent interactions between the C-terminus of 
APC2 and SUMO may contribute to the observed effects of APC4 
sumoylation on APC/C activity.  To test this hypothesis, we generated stable 
cell lines allowing for inducible expression of FLAG-tagged wild type 
APC2 or the APC2 SIM mutant defective (APC2SM) in SUMO binding. 
Endogenous APC2 was depleted by siRNA knockdown in the presence and 
absence of concomitant transgene expression (Figure 6B) and effects on cell 
cycle progression were evaluated by timelapse microscopy. As expected, 
depletion of APC2 resulted in severe mitotic defects comparable to those 
observed in APC4-depleted cells, although defects were only observed in 
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~50% of cells, presumably due to incomplete knockdown (Figure 6B and C). 
Expression of FLAG-APC2 SIM mutant was much less effective than 
expression of wild type FLAG-APC2 in rescuing APC2 depletion defects. In 
particular, although all cells progressed from NEBD to metaphase normally, 
a significant fraction exhibited prolonged metaphase delays comparable to 
those observed in APC4KR expressing cells (Figure 6D-G). On average, 
APC2 cells spent 24.53 minutes to progress from NEBD-metaphase and 
18.3 minutes from metaphase to anaphase, while APC2SM cells spent 24.43 
minutes to progress from NEBD-metaphase and 35.07 minutes from 
metaphase to anaphase. These findings support the notion that APC2 SUMO 
binding promotes APC/C activity and anaphase onset. Because the C-
terminal domain of APC2 plays a critical role in recruiting and positioning 
UbcH10~Ub for catalysis and is flexible56,57, we propose that APC4 
sumoylation stabilizes a conformation that is optimal for UbcH10 binding 
and substrate modification (Figure 7).  
 
SIM binding is required for APC/C function 
 To evaluate if SUMO recognition by the SIM in APC2 is functionally 
important, we generated mutations in the second b-strand of SUMO2 critical 
for SIM binding59–61. A stable cell line expressing a SIM binding mutant was 
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expressed, wherein alanine substitutions at glutamine 35, phenylalanine 36, 
and isoleucine 38 (SUMO2-QFI or SUMO2QFI) were made to the linear 
FLAG-APC4KR-S2 transgene (Figure 7A). Following endogenous APC4 
depletion and doxycycline-induced expression (Figure 7C), cells were 
imaged using timelapse microscopy. On average, control cells spent 28.59 
minutes from NEBD-metaphase, while APC4KRSUMO2QFI expressing cells 
spent 34.89 minutes. This difference is not statistically significant difference 
(p = 0.097). However, control cells spent 18.28 minutes on average 
transitioning from metaphase-anaphase, while APC4KRSUMO2QFI cells 
spent 53.15 minutes, a statistically significant difference (p = 0.0011). These 
data rule out the possibility that APC4 sumoylation has steric effects on 
APC/C activity and demonstrate that SIM recognition of sumoylated APC4 





 During early stages of mitosis, the SAC generates well characterized 
inhibitory signals to block APC/C activity and anaphase onset2,4–6. Signals 
and mechanisms acting downstream of SAC silencing that function to 
regulate APC/C activity and specificity, however, are less well understood. 
Here, we have shown that sumoylation is required for optimal activation of 
APC/C following chromosome alignment and checkpoint silencing. We 
have identified sumoylation sites in the C-terminus of APC4 and a SIM in 
the cullin-homology domain of APC2 that are both critical for optimal 
APC/C function at the metaphase-anaphase transition. Based on our 
findings, we propose that interactions between sumoylated APC4 and APC2 
stabilize a conformation of the APC/C catalytic core that enhances E2 
binding and substrate ubiquitylation.  
 
APC4 Sumoylation Stimulates the APC/C 
Several lines of evidence indicate that sumoylation is required for 
APC/C activity after SAC is satisfied. First, cells expressing sumoylation 
deficient APC4KR, SUMO-binding deficient APC2SM, and SIM-binding 
deficient APC4KRSUMO2QFI undergo normal progression from NEBD to 
metaphase plate alignment, but exhibit delays during the metaphase-
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anaphase transition, accompanied by delays in Cyclin B1 degradation. 
Second, mimicking constitutive APC4 sumoylation through expression of 
APC4KR-S2 had no adverse effects on progression through mitosis, 
demonstrating that APC4 sumoylation alone is insufficient to affect APC/C 
activation prior to SAC silencing. Furthermore, APC4KR-S2 rescued the 
metaphase delay observed in APC4KR cells, further suggesting that 
sumoylation functions downstream of checkpoint silencing to stimulate 
APC/C activity. Additional analysis of kinetochore localization of SAC 
proteins in APC4 and APC4KR-expressing metaphase cells indicated that 
sumoylation is not required to downregulate MCC assembly at kinetochores. 
Finally, weakening the SAC with the Mps1 kinase inhibitor reversine 
significantly reduced total mitotic timing and precocious anaphase in APC4 
cells but not in APC4KR cells. Importantly, whether APC4 sumoylation 
affects MCC disassembly from the APC/C is yet unknown.  
Metaphase delays downstream of SAC inactivation like those 
observed in APC4KR-, APC2SM-, and APC4KRSUMO2QFI expressing cells are 
unusual and have only been observed in a limited number of cases. In one 
example, the spindle and kinetochore-associated (Ska) complex has been 
proposed to promote APC/C localization to chromosomes with the effect of 
stimulating Cyclin B1 and securin degradation62. Although it is unclear how 
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chromosomal localization affects APC/C activity, it is interesting to 
speculate that this may involve sumoylation of APC4 by one of the known 
chromosome-associated SUMO E3 ligases, RanBP2/Nup358 or PIASg63,64. 
Additionally, mutations that inactivate Ube2S, the ubiquitin E2 conjugating 
enzyme responsible for elongating K11-linked polyubiquitin chains on 
APC/C substrates, also lead to delays in anaphase onset65. This defect is due 
in part to inefficient turnover of inhibitory MCC proteins, and is thus 
checkpoint dependent16. While we have ruled out a dependence on SAC 
signaling using the Mps1 kinase inhibitor reversine, APC4KR- and APC4SM-
expressing cells may similarly be affected by reduced turnover of MCC 
proteins.  
 
Temporal regulation of APC4 sumoylation 
APC4 sumoylation is detectable in all other stages of the cell cycle, 
but peaks during the metaphase-anaphase transition. The factors controlling 
APC4 sumoylation levels remain largely uncharacterized, but may include 
SUMO E3 ligases. For example, RanBP2 and PIASg control sumoylation of 
topoisomerase I I a (Topo IIa) during mitosis. In mouse embryonic 
fibroblasts, RanBP2 mediates SUMO1 modification of Topo IIa resulting in 
appropriate localization to inner centromeres and promoting DNA 
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decatenation63. Furthermore, in Xenopus egg extracts, PIASg mediates 
SUMO2/3 modification of Topo IIa, regulating appropriate disjunction of 
sister chromatids before anaphase64. Both RanBP2 and PIASg localize to 
centromeres during mitosis, and may also regulate APC4 sumoylation in a 
spatiotemporal manner, as APC/C also localizes to centromeres during 
mitosis. Further characterization of SUMO E3 ligases affecting APC4 
modification will deepen our current understanding of SUMO-dependent 
APC/C activation.  
Another possible regulator of APC4 sumoylation during mitosis is the 
SUMO isopeptidase, SENP1. SENP1 is a critical for timely progression 
during the metaphase-anaphase transition26. Notably, SENP1 depletion leads 
to elevated levels of APC4 sumoylation, suggesting that APC4 is a bona fide 
substrate (Sup. Figure 1C). APC4 sumoylation levels increase specifically 
during the metaphase-anaphase transition, followed by a subsequent 
decrease coinciding with Cyclin B1 degradation. These collective findings 
suggest that the dynamic regulation of APC4 sumoylation may be under the 
spatiotemporal control of SENP1 activity. How SENP1 function or 
recognition of APC4 may be temporally regulated throughout the cell cycle 
remains to be determined. Furthermore, the C-terminus of APC4 is 
phosphorylated at residues S777 and S779 during mitosis19 that lie in close 
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proximity to the APC4 sumoylation sites. Previous evidence for 
phosphorylation-dependent sumoylation has been described24,66, leaving an 
additional possibility that APC4 sumoylation may also be under the 
regulatory control of mitotic kinases.  
 
Sumoylation as a modulator of the catalytic core  
Canonical cullin-RING ligases include cullin and RING proteins, and 
the catalytic center of the APC/C is composed of APC2 and APC11, which 
contain cullin and RING homology domains, respectively. Domains within 
the C-terminus of APC2, including the cullin homology domain, facilitate 
cooperative interactions with APC11 and a partner E2, UbcH10 (Figure 5B). 
Specifically, a C-terminal α/β domain is essential for binding APC11-RING, 
and a distal winged helix B (WHB) domain makes direct contacts with 
UbcH1055,57. Substrate ubiquitylation is thus dependent on the coordination 
of the cullin-RING-E2 module, which forms the active site of the APC/C. 
APC2-11 is known to adopt multiple conformations that are responsive to 
MCC binding and release, Cdc20 co-activator binding, and the recruitment 
of ubiquitin-charged UbcH1014,55–57. How dynamics of the catalytic center 
are regulated and how specific conformations of the catalytic center are 
stabilized are yet unknown. Recent structural studies have shown that 
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UbcH10 binding is one factor that limits the degrees of freedom of APC2-
1157. Functional studies have shown that binding and stabilizing interactions 
between APC2 and UbcH10 are required for optimal substrate 
ubiquitylation17. Therefore, subtle changes in conformation and stability 
induced by UbcH10 binding have significant effects on activity. Our studies 
have identified sumoylation as another mechanism for affecting 
conformation and stability of the catalytic core. 
We have identified a functionally important SIM, located within the 
cullin homology domain of APC2 and linking the α/β and WHB domains 
(Figure 5B). The position of this SIM suggests that SUMO binding stabilizes 
a conformation of the catalytic core optimal for UbcH10 recruitment, APC/C 
catalysis and substrate ubiquitylation. Both the APC4 SUMO modification 
sites and the APC2 SIM are conserved in mammals (Sup. Figure 1A, Figure 
5B), consistent with a functional connection between these domains in 
higher eukaryotes. Notably, both the APC4 sumoylation sites and the SIM 
are located within domains that are unstructured in current structures. We 
propose that sumoylation stabilizes these flexible domains and importantly, 
the catalytic core of the APC/C. Consistently, our in vivo studies show that 
both APC4 SUMO and APC2 SIM mutants result in metaphase-anaphase 
delays, indicative of defects in APC/C activity. The linear APC4KRSUMO2 
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fusion rescues the metaphase-anaphase delay observed in the APC4KR 
mutant, while mutations in SUMO2 that disrupt SIM recognition does not. 
Taken together, these data establish a functional relationship between APC2 
SIM recognition and APC4 sumoylation during the metaphase-anaphase 
transition. Finally, in vitro studies demonstrate that APC4 sumoylation 
stimulates APC/C-mediated Cyclin B1 ubiquitylation. A formal test of our 
model will benefit from structural studies of sumoylated APC/C.  
There is precedence for ubiquitin-like modifications of other cullin-
RING E3s that influence catalysis. For example, NEDD8 modifies a lysine 
residue in the cullin of Rbx1 that leads to conformational changes and 
prevents binding of the Rbx1 inhibitor, CAND167. NEDDylation releases the 
cullin-RING domain of Rbx1 from conformational constraints, which results 
in enhanced catalysis and substrate ubiquitylation67. In contrast, we propose 
that sumoylation of APC4 stabilizes a conformation that limits the 
geometries of the cullin-RING-E2 catalytic module, resulting in APC/C 
activation. NEDDylation of APC/C subunits have yet to be characterized. 
However, NEDDylation likely regulates cullin-RING E3 ligases through 
mechanisms distinct from sumoylation, and it is unlikely that sumoylation 
replaces the functional role of NEDDylation in the context of the APC/C or 
other cullin-RING E3 ligases.  
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SUMO has been previously found to affect multiple other enzymatic 
processes. For example, sumoylation has been proposed to promote the 
turnover of thymidine DNA glycosylase (TDG) during base excision repair. 
Structural studies suggest that sumoylated TDG adopts different 
conformations mediated by intramolecular SIM interactions, reducing 
affinity to DNA in vitro68,69. However, it remains to be determined if this 
model holds true in vivo70. In addition, SUMO modification is important for 
other cellular processes such as transcription, chromatin remodeling, and 
DNA damage repair23. Furthermore, ribosomes29, PML nuclear bodies27,28,71, 
and kinetochores30–32 require SUMO modification for assembly and activity. 
In these examples, SUMO functions by enhancing protein-protein 
interactions through non-covalent SIM binding to promote assembly of 
functional complexes. In contrast to these previously characterized 
examples, we propose that APC4 SUMO modification is a stabilizing factor 
mediating intermolecular interactions of a pre-assembled molecular 
machine. This novel role for sumoylation may also function to stabilize and 
coordinate SUMO-SIM interactions across proteins within other pre-
assembled complexes, thereby regulating protein conformation and 
modulating function.  
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In summary, we have shown that both covalent SUMO modification 
and non-covalent SIM-mediated binding play important roles in regulating 
APC/C activity and mitotic exit. We propose that SUMO-SIM interactions 
function to stabilize the cullin-RING-E2 module of the multi-subunit APC/C 
in an active conformation, thereby stimulating catalytic activity. While 
additional molecular mechanisms affecting APC/C activity downstream of 
checkpoint silencing have yet to be determined, here we identify 
sumoylation as a critical post-translational regulator of the metaphase-
anaphase transition. Importantly, inhibitors to the SUMO pathway are 
currently being developed for chemotherapeutic use, and our studies provide 
molecular insights into how these inhibitors may function to inhibit cell 
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APC4 is sumoylated in a cell-cycle dependent manner at two C-terminal 
lysines.  
(A) HeLa cells were synchronized in S-phase using a double-thymidine 
arrest and released for varying time points. Whole cell lysates were analyzed 
by immunoblotting for APC4, Cyclin B1, Cdc20, and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as a loading control. Asterisks indicate 
sumoylated forms of APC4. (B) APC4 contains two C-terminal SUMO 
consensus site lysines at 772 and 798. (C) Full length wild type APC4 or the 
indicated lysine to alanine substitution mutants were expressed in rabbit 
reticulocyte lysate in the presence of [35S]-methionine and incubated for the 
indicated times in modification reactions containing SUMO E1 and E2 
enzymes and SUMO2. Proteins were detected by SDS-PAGE and 
autoradiography. Asterisks indicate sumoylated forms of APC4. (D) 
Constructs coding for FLAG-tagged versions of wild type APC4 or a 
sumoylation-deficient mutant containing arginine substitutions at lysines 772 
and 798 (APC4KR) were used to generate stable inducible cell lines in YFP-
H2B HeLa cells. (E) Endogenous APC4 was depleted by siRNA, and 
FLAG-APC4 or FLAG-APC4KR stable cell lines were induced by 
doxycycline for 48 h. Immunoblot analysis using APC4 and tubulin specific 
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antibodies reveals that FLAG-APC4 and FLAG-APC4KR are expressed at 
near endogenous levels. (F-G) Co-immunoprecipitations were performed 
with an antibody against APC4, followed by immunoblotting for APC4 or 
SUMO2. FLAG-APC4 is sumoylated in vivo while FLAG-APC4KR is not. 








APC4 is sumoylated in vivo and in vitro at two C-terminal lysine 
residues; APC4 sumoylation is regulated by SENP1. 
(A) U2OS or 6xHis-SUMO2 U2OS cells were synchronized in different 
stages of the cell cycle. Cells were lysed in 6M guanidine HCl lysis buffer, 
immunopurified with Ni-NTA agarose, washed in buffers containing 8M 
urea, and analyzed by SDS-PAGE and immunoblotting with antibodies 
against APC4 or SUMO2/3. Single asterisks (*) indicates SUMO modified 
forms of APC4. A double asterisk (**) indicates unconjugated 6xHis-
SUMO2. (B) Full length APC4 was expressed in vitro and incubated for the 
indicated times in modification reactions containing SUMO E1 and E2 
enzymes and SUMO1. Proteins were detected by autoradiography. APC4 
lysine to alanine single mutant (APC4K772A and APC4K798A) and a double 
mutant (APC4K772/798A) were expressed in vitro and incubated with 
recombinant SUMO1. Asterisks (*) indicate sumoylated forms of APC4. (C) 
Endogenous APC4 was depleted by siRNA, and APC4 WT or APC4KR were 
induced by doxycycline for 48 h. Co-immunoprecipitations were performed 
with an antibody against APC4, followed by immunoblotting for APC4 or 
SUMO1. APC4 WT cells are sumoylated in vivo while APC4KR is not. 
Asterisks indicate sumoylated APC4. (D) HeLa cells were treated siRNA 
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oligos targeting a control, SENP1, or SENP2 as previously described 
(Cubeñas-Potts et al. 2013b). 36 h following siRNA depletion, cells were 
arrested into S phase with 2mM thymidine for 19 hours, released for 6 h 
using a 100 ng/mL nocodazole treatment, followed by a 2 hr treatment with 
MG132 to synchronize into metaphase. Whole cell lysates were 
immunoblotted with antibodies specific for APC4, SENP1, SENP2, and 







APC4 sumoylation is required for normal metaphase to anaphase 
transition. (A) Cells were treated with or without siRNA to APC4 (Control 
or siAPC4) for 48 hours followed by 16 hours of timelapse live cell 
acquisition. siAPC4 treated cells were also induced to express FLAG-APC4 
or FLAG-APC4KR. Analysis represents mitotic progression time beginning 
with nuclear envelope breakdown (NEBD) to anaphase onset. Quantification 
of mitotic phenotypes is shown. Prolonged metaphase is defined by >60 min 
in metaphase plate alignment before anaphase onset. Abnormal metaphase is 
defined by inability to generate a metaphase plate and defects in 
chromosomal cohesion. n > 100 for each cell line. (B) Cells representative of 
each mitotic phenotype categorized in (A) are featured with timestamps in 
min. (C) Mitotic progression beginning with NEBD to metaphase plate 
alignment and from metaphase plate alignment to anaphase onset was 
quantified in FLAG-APC4 and FLAG-APC4KR expressing cells. 
Experiments were performed in triplicate; means are displayed and error 
bars represent standard deviations. n = 50 for each cell line. Two-tailed t-
tests were used to calculate significance: p = 0.38 for differences in FLAG-
APC4 and FLAG-APC4KR timing from NEBD-metaphase, p < 0.001 for 
differences in FLAG-APC4 and FLAG-APC4KR timing from metaphase 
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plate alignment to anaphase. (D) Individual timing of metaphase to anaphase 
progression are displayed for FLAG-APC4 and FLAG-APC4KR expressing 
cells. n = 215 for each cell line. (E) Representative cells from timelapse 
acquisition beginning with NEBD to anaphase onset in FLAG-APC4 and 
FLAG-APC4KR expressing cells with timestamps indicated in min. (F) 
FLAG-APC4 and (G) FLAG-APC4KR expressing cells were synchronized in 
S-phase using a double-thymidine arrest and released for various time 
points. Whole cell lysates were analyzed by immunoblotting for APC4, 
Cyclin B1, Cdc20 and GAPDH as a loading control. Asterisks (*) indicate 
sumoylated forms of APC4. (H) Relative protein levels of Cyclin B1 in 
FLAG-APC4 and FLAG-APC4KR cells were quantitated using ImageJ. 






APC4 sumoylation is well-conserved in mammals and APC4 single 
SUMO mutant analysis. 
(A) Multiple sequence alignments for full length APC4 were compared 
using Clustal Omega. (B) Constructs coding for FLAG-tagged versions of 
APC4 sumoylation-deficient mutant containing arginine substitutions at 
lysines 772 or 798 (APC4772R/APC4798R) were used to generate stable 
inducible cell lines in YFP-H2B HeLa cells. (C) Endogenous APC4 was 
depleted by siRNA, and FLAG-APC4772R or FLAG-APC4798R stable cell 
lines were induced by doxycycline for 48 h. Immunoblot analysis using 
APC4 and tubulin specific antibodies reveals that FLAG-APC4772R and 
FLAG-APC4798R are expressed at near endogenous levels. (D) Cells were 
treated with or without siRNA to APC4 (Control or siAPC4) for 48 hours 
followed by 16 hours of timelapse live cell acquisition. Representative cells 
are featured with timestamps in minutes. (E) Mitotic progression beginning 
with NEBD to metaphase plate alignment and from metaphase plate 
alignment to anaphase onset was quantified in FLAG-APC4772R and FLAG-
APC4798R expressing cells. Experiments were performed in triplicate; means 
are displayed and error bars represent standard deviations. n > 100 for each 
cell line. Two-tailed t-tests were used to calculate significance: p = 0.1551 
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for differences in Control vs. and FLAG-APC4772R timing from NEBD-
metaphase, p = 0.0724 for differences in Control vs. FLAG-APC4798R timing 
from NEBD-metaphase; p = 0.0306 for differences in Control vs. FLAG-
APC4772R and p = 0.0338 for differences in FLAG-APC4798R timing from 
metaphase plate alignment to anaphase, respectively. (D) Individual timing 
of metaphase to anaphase progression are displayed for FLAG-APC4772R 





















APC4 sumoylation does not affect APC/C or MCC localization at 
kinetochores.  
(A) Stable inducible cell lines were depleted of endogenous APC4 using 
siRNA for 48 hours with concomitant induction of FLAG-APC4 or FLAG-
APC4KR expression. Cells were stained with FLAG and CREST specific 
antibodies and analyzed by immunofluorescence microscopy. Boxed regions 
are magnified to show c-localization at kinetochores during prometaphase 
and metaphase. (B) Inducible cell lines were treated as in (A) and stained 
with antibodies specific to Mad1, Mad2, BubR1, and Cdc20 as indicated. 
Chromatin (colored in teal) was visualized by detection of YFP-H2B 








APC4 Sumoylation is critical downstream of Spindle Assembly 
Checkpoint inactivation 
(A) Endogenous APC4 was depleted by siRNA, and FLAG-APC4 or 
FLAG-APC4KR stable cell lines were induced by doxycycline for 48 h. 
Immunoblot analysis using APC4 and tubulin specific antibodies reveals that 
FLAG-APC4 and FLAG-APC4KR are expressed at near endogenous levels. 
(B) Cells were treated with reversine immediately prior to 4 hr timelapse 
acquisition, and timing from NEBD to anaphase onset (mitotic exit timing) 
was collected. Data are representative of 4 independent experiments, n = 23 
for each cell line. On average, FLAG-APC4 cells take 48.65 min to mitotic 
exit (Standard Deviation = SD = 15.99) while reversine treated FLAG-APC4 
cells take 34.87 min (SD = 11.00). This difference is significant (p = 
0.0014). FLAG-APC4KR cells take 81.48 min to mitotic exit (SD = 30.78) 
while reversine treated FLAG-APC4KR cells take 78.78 min (SD = 21.41). 
This difference is not statisitically significant (p = 0.73). Two-tailed t-tests 
were used to calculate significance. (C-F) Representative cells from 
timelapse acquisition beginning with NEBD to anaphase onset in cells with 










APC4 sumoylation functions downstream of checkpoint inactivation to 
affect APC/C activity.  
(A) A construct coding for a FLAG-tagged APC4KR-SUMO2 fusion protein 
(APC4KR-S2) was used to generate stable inducible lines in YFP-H2B HeLa 
cells. (B) Cells were transfected with or without APC4-targeting siRNAs 
and cultured in the presence (+Dox) or absence of doxycycline. Endogenous 
APC4 and FLAG-APC4KR-S2 expression levels were analyzed by 
immunoblot analysis with APC4 and tubulin specific antibodies. (C) 
Representative cells from timelapse acquisition beginning with NEBD to 
anaphase onset in control and FLAG-APC4KR-S2 expressing cells with 
timestamps indicated in min. (D) Mitotic timing beginning with NEBD to 
metaphase plate alignment and from metaphase plate alignment to anaphase 
onset was quantified in control and FLAG-APC4KR-S2 expressing cells. 
Experiments were performed in triplicate; means are displayed and error 
bars represent standard deviations. n = 60 for each cell line. Two-tailed t-
tests were used to calculate significance: p = 0.16 between control and 
FLAG-APC4KR-S2 timing from NEBD-metaphase, p = 0.35 for control and 
FLAG-APC4KR-S2 timing from metaphase plate alignment to anaphase. (E) 
Individual timing of metaphase to anaphase transition times is displayed for 
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control and FLAG-APC4KR-S2 expressing cells. n = 314 for each cell line. (F 
and G) APC/C was immunopurified from FLAG-APC4 or FLAG-APC4KR-S2 
expressing cells using FLAG-specific antibodies followed by immunoblot 
analysis with APC4 or APC2 specific antibodies. (H) In vitro ubiquitylation 
assays were performed using APC/Cs immunopurified from FLAG-APC4 or 
APC4KR-S2 expressing cells. Reactions were incubated with recombinant 
myc-Cyclin B1 for varying times and analyzed by immunoblotting with anti-
myc antibodies (I) Reactions were performed in triplicate and mean relative 
myc-Cyclin B1 ubiquitylation levels is shown with error bars indicating the 









APC2 contains a conserved C-terminal SIM 
(A) APC2 (pink) contains a predicted SIM (red) near its C-terminus that is in 
close proximity to the C-terminus (blue) of APC4 (teal). (PDB ID: 
5LCW(Alfieri et al. 2016)). (B) Schematic depicting the APC2 SIM (red) 
between residues 727-738 and its conservation in mammals. Previously 
characterized (Brown et al. 2015) a/b and WHB domains extend from 
residues 549-727 and 735-822, respectively. Alanine substitutes at V728 and 
L729 were used to generate a SIM Mutant. (C) APC2 and an APC2 SIM 
mutant were produced in rabbit reticulocyte lysate in the presence of [35S]-
methionine. The expressed proteins were incubated with immobilized, 
recombinant GST or GST-SUMO2 trimer (SUMOx3) and binding was 
analyzed by SDS-PAGE and autoradiography. (E) Quantitation from 3 
independent binding assays. Values from scintillation counting were used to 
generate relative binding ratios. Means are plotted and bars represent 
standard deviations. Two-tailed t-tests were performed: p = 0.04 for APC2 
wild type binding to GST-SUMOx3/GST, p = 0.08 for APC2 SIM Mutant 






Characterization of APC2 SIM binding 
 
Truncated constructs of APC2 were generated. (B) In vitro binding assays of 
various APC2 constructs expressing wild type APC2 or a (C) C-terminal 
SIM Mutant were performed using recombinant GST or a GST-SUMO2 
trimer (SUMOx3). (D) Quantitation from 3 independent replicates indicate 
the relative SUMO/GST binding between APC2 and APC2 SIM Mutant. 
Values from scintillation counting were used to generate ratios of relative 
binding. Means are plotted and bars represent standard deviations. Two-
tailed t-tests were performed, p = 0.22 for APC2 C binding to GST-
SUMOx3/GST, p = 0.75 for APC2 D binding to GST-SUMOx3/GST, p = 
0.01 for APC2 E binding to GST-SUMOx3/GST, and p = 0.18 for APC2 E 






The APC2 SIM is required for normal progression from metaphase to 
anaphase.  
(A) Constructs coding for FLAG-tagged versions of wild type APC2 or the 
SIM mutant (APC2SM) were used to generate stable inducible cell lines in 
YFP-H2B HeLa cells. (B) Cells were transfected with or without APC2-
targeting siRNAs (Control or siAPC2) and cultured in the presence (+Dox) 
or absence of doxycycline. Endogenous APC2, FLAG-APC2 and FLAG-
APC2SM expression levels were analyzed by immunoblot analysis with 
APC2 and tubulin specific antibodies. (C) Mitotic phenotypes observed in 
cells treated as in (B) are displayed. n > 130 for each cell line. (D) 
Representative cells from timelapse acquisition beginning with NEBD to 
anaphase onset in FLAG-APC2 and FLAG-APC2SM expressing cells with 
timestamps indicated in minutes. (F) Mitotic timing beginning with NEBD 
to metaphase plate alignment and from metaphase plate alignment to 
anaphase onset was quantified in FLAG-APC2 and FLAG-APC2SM 
expressing cells. Experiments were performed in triplicate; means are 
displayed and error bars represent standard deviations. n = 59 for each cell 
line. Two-tailed t-tests were used to calculate significance: p = 0.912 
between FLAG-APC2 and FLAG-APC2SM timing of NEBD-metaphase, p < 
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0.001 for FLAG-APC2 and FLAG-APC2SM timing from metaphase plate 
alignment to anaphase. (E) Individual timing of metaphase to anaphase 
transition times is displayed for FLAG-APC2 and FLAG-APC2SM 












SIM binding is required for normal progression from metaphase to 
anaphase 
(A) Constructs coding for FLAG-tagged versions of linear APC4KRSUMO 
deficient of SIM binding (SUMO2-QFI) was used to generate stable 
inducible cell lines in YFP-H2B HeLa cells. (B) The crystal structure of 
SUMO2 (PDB ID: 1WM3 (Huang et al. 2004)) with the SIM binding 
mutations in the second b-strand (highlighted in yellow) are shown. (C) 
Cells were transfected with control or APC4-targeting siRNAs (Control or 
siAPC4) and cultured in the presence (+Dox) or absence of doxycycline. 
Endogenous APC4 and FLAG-APC4KRSUMO2QFI expression levels were 
analyzed by immunoblot analysis with APC4 and tubulin specific 
antibodies. (D) Representative cells from timelapse acquisition beginning 
with NEBD to anaphase onset in control and (E) FLAG-APC4KRSUMO2QFI 
expressing cells with timestamps indicated in mins. (F) Mitotic timing 
beginning with NEBD to metaphase plate alignment and from metaphase 
plate alignment to anaphase onset was quantified in control and FLAG-
APC4KRSUMO2QFI expressing cells. Experiments were performed in 
triplicate; means are displayed and error bars represent standard deviations 
(SD). n =101 for each cell line. Two-tailed t-tests were used to calculate 
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significance: p = 0.097 (not significant) between Control (average = 28.59 
min, SD = 2.19) and FLAG-APCKRSUMO2QFI (average = 34.89 min, SD = 
1.93) timing of NEBD-metaphase, p = 0.0011 for Control (average = 18.28 
min, SD = 1.57) and FLAG-APC4KRSUMO2QFI (average = 53.15 min, SD = 
3.85) timing from metaphase plate alignment to anaphase. (E) Individual 
timing of metaphase to anaphase transition times is displayed for Control 
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FIGURE 2-12 
A model for SUMO-mediated enhancement of APC/C activity involving 
APC4 sumoylation and APC2 SUMO binding.  
(A) Activated APC/C adopts an open conformation competent for sub-
optimal E2~Ub interactions. (B) APC4 sumoylation and interactions 
between SUMO and the APC2 SIM stabilizes a conformation between the 
APC2-WHB domain and APC11-RING (C). Stabilization of APC2-11 by 


































 Cell cycle progression is carefully coordinated so that equivalent 
copies of replicated DNA are equally divided during mitosis. Aberrations 
during this process can result in the gain or loss of genetic information, a 
phenomenon known as aneuploidy. Aneuploidy is one of the key hallmarks 
of cancer cells, and a fundamental understanding of mitosis will allow us to 
address strategies to prevent tumorigenesis.  
 Several regulatory checkpoints during mitosis ensure that sister 
chromosomes segregate equally. Post-translational modifications such as 
phosphorylation and ubiquitylation are classic drivers and regulators of the 
Spindle Assembly Checkpoint (SAC) and the activity of the Anaphase 
Promoting Complex/Cyclosome (APC/C). Here we present evidence that the 
SUMO isopeptidase SENP1 has critical roles in regulating the metaphase-
anaphase transition. Localization analysis of the sequence elements in the N-
terminal domain show that SENP1 is targeted to the nuclear pore complex 
(NPC) during interphase, and to kinetochores, spindle microtubules, and 
centromeres during mitosis. Here we also present analysis from proximity-
dependent biotin identification (BioID) of SENP1, which validate 
localization studies. Immunofluorescence analysis of SAC proteins at the 
NPC during interphase, together with functional assays using timelapse 
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microscopy, suggest a role for SENP1 activity as a critical determinant of 





 During the mitotic stage of the cell cycle, equal segregation of 
duplicated chromosomes must be carefully coordinated in order to maintain 
genomic integrity. Aberrations in mitosis can result in gains or losses of 
chromosomes in part or in whole, a condition known as aneuploidy1. The 
ability of aneuploid cells to overcome cellular safeguards and further 
replicate is a key hallmark of tumorigenesis2. Thus, the cellular surveillance 
mechanisms to ensure the fidelity of chromosome segregation must be 
exquisitely regulated. While mitosis has been observed for over a hundred 
years3, and several key contributions have shaped our current understanding 
of this essential cellular process, there are yet outstanding questions 
regarding how events are coordinated, particularly during the metaphase-
anaphase transition. Here we demonstrate the importance of regulation by 
the post-translational modification Small Ubiquitin-related Modifier 
(SUMO) during mitosis and its role in appropriately timing mitotic 
progression. 
 One of the initiating mitotic events is the dissolution of the nuclear 
membrane, or nuclear envelope breakdown (NEBD). Components of the 
nuclear membrane reorganize during mitosis, including the disassembly of 
nuclear pore complexes (NPCs) and nuclear lamina depolarization, which 
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are both regulated by phosphorylation events4–6. Components of the NPC, 
including the Nup107 complex, Nup358, Rae1, and Tpr function to 
coordinate kinetochore assembly, recruitment and pre-assembly of mitotic 
checkpoint protein factors7–12. Concurrent with NEBD, chromosomes 
condense and organize to form a metaphase plate, sister chromosomes 
become encircled by cohesins, and kinetochores come under attachment 
with the mitotic spindle. Kinetochores that have not been captured by 
spindle microtubules are regulated by the Spindle Assembly Checkpoint 
(SAC)13, and require multiple inputs from mitotic kinases to coordinate 
amphitelic attachments14. The SAC produces an inhibitory signal consisting 
of proteins forming the Mitotic Checkpoint Complex (MCC) including 
BubR1, Bub3, Mad2, and together with the co-activator Cdc20, bind to and 
inhibit the activity of the Anaphase Promoting Complex/Cyclosome 
(APC/C)15,16. The APC/C is a RING E3 ubiquitin ligase that facilitates the 
proteolysis of Cyclin B1 and securin, culminating in the segregation of sister 
chromosomes17. Broadly, post-translational modifications by mitotic kinases 
and the ubiquitin system are indispensable drivers of mitosis. Here we 
present essential roles for an additional post-translational modification—
components of the SUMO pathway—in regulating mitotic progression. 
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 SUMO regulates a variety of cellular events, including transcription, 
ribosome biogenesis, chromatin remodeling, and chromosome segregation18–
20. Invertebrates and yeast express a single SUMO, while higher eukaryotes 
express three functional SUMO isoforms, SUMO1, SUMO2 and SUMO3. 
SUMO1 is ~45% identical to SUMO2 and SUMO3, with potentially distinct 
cellular functions, whereas SUMO2 and SUMO3 share ~96% sequence 
homology and are collectively referred to as SUMO2/3. Like ubiquitin, 
SUMO is first processed by an isopeptidase to expose a C-terminal di-
glycine motif used for conjugation. SUMO is a covalent modification 
whereby attachment to a substrate is achieved by a sequential enzymatic 
cascade involving an activating E1 (heterodimer of Aos1/Uba2), a single 
conjugating E2 (Ubc9), and several ligating E3 enzymes. SUMO 
modification results in the formation of an isopeptide linkage between the C-
terminal glycine of SUMO with the e-amine of the substrate lysine18. The 
consensus site sequence for SUMO modified substrates is represented by a 
y-K-x-E/D motif, whereby y represents a hydrophobic residue, K is the 
substrate lysine, x is any amino acid, followed by an acidic residue, either 
glutamic or aspartic acid. SUMO modification can result in redirected 
localization of substrates, in addition to generating non-covalent interactions 
between a SUMO modified substrate and a protein containing a SUMO 
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Interacting Motif (SIM). As a result, sumoylation influences protein 
activities in a variety of essential cellular processes21. Physiologically, 
perturbations to the SUMO pathway, such as overexpression of the SUMO 
deconjugating enzymes, have been implicated in a variety of human 
cancers22. Thus, the balanced regulation of SUMO pathway components is 
critical for human health. 
 Since its initial discovery, SUMO has been characterized as an 
essential regulator of mitotic progression. The single SUMO gene identified 
in S. cerevisiae, SMT3 (Suppressor of Mif Two), emerged from a suppressor 
screen of MIF2, a gene encoding a distant homolog of the mammalian 
centromere CENP-C protein21,23. SMT3 is essential for mitotic progression, 
as smt3 mutants arrest in mitosis. The SUMO homolog in S. pombe, Pmt3, 
also has critical roles in normal chromosome segregation and mitotic 
progression24. Since the identification of sumoylated RanGAP1 in human 
cells at nuclear pore complexes25,26, mechanistic roles of the RanGAP1-
SUMO complex with the nucleoporin Nup358/RanBP2 have also been 
shown to coordinate mitotic events27. During mitotic initiation, 
Nup358/RanBP2 functions to integrate nuclear envelope breakdown with 
kinetochore assembly10. During mitosis, Nup358/RanBP2 also functions as a 
SUMO E3 ligase, and facilitates the SUMO modification of Topoisomerase 
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IIa at kinetochores28. Additional roles for SUMO in regulating mitotic 
events have emerged, including the decatenation of chromosome arms 
regulated by Topoisomerase IIa28,29, kinetochore-microtubule interactions30–
32, and checkpoint signaling33–35. Furthermore, recent high-throughput mass 
spectrometry analyses have diversified the catalog of the SUMO proteome, 
and the identification of SUMO substrates during mitosis widens the 
potential for discovering novel regulatory roles36–38.  
 At steady state levels, the abundance of the SUMO modified substrate 
is relatively low, and the regulatory axis of conjugation and deconjugation is 
mediated in part by SUMO isopeptidases. Several classes of SUMO 
isopeptidases include the Ulp (UBL-specific protease) family first identified 
in S. cerevisiae39, the sentrin-specific proteases (SENPs) in humans40, 
desumoylating isopeptideses (DeSIs)41, and ubiquitin-specific protease-like 
enzyme (USPL1)42.  All of these proteins function as cysteine proteases. The 
human SENPs share a conserved C-terminal catalytic domain, but contain 
divergent N-terminal domains that confer distinct sub-cellular localizations 
and functions43. SENPs are the best studied class of SUMO isopeptidases, 
and roles for regulating mitotic events have been reported45. We have, for 
example, shown that depletion of SENP1 from cultured mammalian cells 
results in defects in the timing of mitotic exit20. However, the specific 
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SUMO substrates recognized by SENP1, and the molecular mechanisms 
regulating its localization and functions in mitosis, remain poorly 
understood. 
   Here, we elaborate on the role of SENP1 in regulating the metaphase-
anaphase transition. Defects in appropriate timing of the metaphase-
anaphase transition in SENP1 depleted cells could be based on several 
possibilities: (1) inappropriate kinetochore-microtubule capture and 
appropriate tension during prometaphase, (2) defects in recruitment or 
accumulation of SAC proteins at kinetochores during prometaphase and 
metaphase, (3) incomplete inactivation of the SAC, (4) interactions at NPCs 
during interphase related to the pre-assembly of SAC complexes. By 
analysis of each of these possibilities, our data suggest that SENP1 depletion 
results in the accumulation of Mad1 and Mad2 at NPCs during interphase, 
which ultimately affects the timing of mitotic exit. We further define 
sequence elements in the N-terminus of SENP1 that direct targeting to 
components of the NPC during interphase, and to kinetochores, 
centrosomes, and spindle microtubules during mitosis. Proteomic analysis 
using proximity-dependent biotin identification (BioID) confirmed 
interactions of N-terminal SENP1 domains with subunits of the NPC. 
Finally, functional assays with truncation mutants of SENP1 suggest that 
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binding interactions with the Nup107 complex are critical for normal mitotic 
progression. These collective findings lend additional mechanistic insights 




MATERIALS AND METHODS 
 
Cell culture, cell lines, plasmids, and drug treatments 
 293FT, JW36 HeLa and YFP-H2B HeLa cells (a gift from Andrew 
Holland, Johns Hopkins University, Baltimore, MD) were maintained at 
37°C in a 5% CO2 atmosphere. Cells were grown in DMEM medium 
(Gibco) containing 10% fetal bovine serum (Atlanta Biologicals).  
 GFP-SENP1 constructs were a generous gift from Mary Dasso 
(National Institute of Health, Bethesda, MD). siRNA oligo-resistant GFP-
SENP1 plasmids were generated by PCR-based QuickChange site-directed 
mutagenesis (Strategene, La Jolla, CA) using the wild-type vector as a 
template. SENP1 and N-terminal truncation constructs were PCR amplified 
and inserted into a pmCherry-C2 vector. 
293FT and YFP-H2B HeLa cells were used to generate tetracycline-
inducible cell lines. Lentiviruses containing a blasticidin-resistant 
tetracycline inducible plasmid, in addition to hygromycin-resistant Flag-
APC4, Flag-APC4KR, or mCherry SENP1 transgenes were incorporated via 
lentiviral infection as described previously. In brief, 1 µg of lentiviral DNA 
construct, 800 ng psPAX2 (Addgene, Cambridge, MA, USA), and 200 ng 
pMD2.G (Addgene) were transfected into 293FT cells using XTremeGene 
HP (Roche) according to manufacturer’s instructions. After 48 h, the viral 
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supernatant was filtered through a 0.44 µM PVDF membrane and transduced 
to YFP-H2B HeLa cells in the presence of 8 µg/mL polybrene (Santa Cruz 
Biotechnology). After 24 h, cells were treated with 10 µg/mL blasticidin to 
select for the tetracycline inducible cells for 1 week. Selection for stable cell 
lines was performed with hygromycin B (Roche) at a final concentration of 
200 µg/mL for an additional week concomitant with 10 µg/mL blasticidin 
selection. Individual blasticidin and hygromycin-resistant colonies were 
isolated with cloning discs (after ~2 weeks) and tested for mCherry SENP1 
expression by immunofluorescence microscopy and immunoblot analysis.  
 Thymidine (Sigma-Aldrich) was dissolved in DMSO and used at a 
final concentration of 2 mM. To synchronize cells into S phase, cells were 
cultured in the presence of 2 mM thymidine for 19 h, released in drug-free 
media for 6 h, and cultured in 2 mM thymidine for 19 h. For mitotic 
timecourse analysis, cells were released from the double thymidine block 
and harvested in 2x SDS-sample buffer at indicated timepoints.  
 To inactivate SAC signaling, 1 µM of the Mps1 kinase inhibitor, 
Reversine (Cayman Chemical, Ann Arbor, Michigan), was used 




 JW36 HeLa or YFP-H2B HeLa cells were transfected using 
Lipofectamine RNAiMAX (Invitrogen) and siRNA oligonucleotides at a 
final concentration of 20 nM for 48 hours and before analysis by 
immunoblotting, timelapse microscopy, or immunofluorescence microscopy. 
The following siRNA oligos were used for protein depletion as previously 
described41: scramble control: (5’ –
CUUCCUCUCUUUCUCUCCCUUGUGA-3’), and SENP1 oligo(b): (5’ 
GCAAAUGGCCAAUGGAGAAAUUCUA-3’). 
Two oligonucleotides targeting the 3’ UTR of APC4 were validated, but 
oligonucleotide 2 was used for all experiments. APC4 oligonucleotides were 
purchased from Dharmacon: APC4 Oligo 1: (5’ – 
AGCUUGCCAUUAUUGUGUGUGUAAU – 3’), APC4 Oligo 2: (5’ – 
CAUAGGAGAUGGACUAAGAUGUCUUGG – 3’). 
 
Antibody and imaging techniques 
For immunoblotting, proteins were separated by SDS-PAGE, transferred 
onto nitrocellulose membranes, blocked in 5% milk in TS-T, and then 
probed with the following antibodies diluted in PBS supplemented with 2% 
BSA and 0.05% NaN3: Centrin (CEN, mouse, 1:3000, a generous gift from 
Phil Jordan), Cyclin B1 (mouse, GNS1: sc-245, 1:200, Santa Cruz 
Laboratories), GAPDH (rabbit, TAB1001, OpenBiosystems, 1:15,000), 
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mCherry (rabbit, 1:10,000 a generous gift from Jiou Wang), Myc (mouse, 
9E10, 1:2000), SENP1 (rabbit, ab108981, 1:10,000, Abcam), SUMO-2/3 
(8A2, 1:800), and Tubulin (mouse, DM1A, 1:5000, Sigma-Aldrich. 
Secondary antibodies conjugated to HRP (Jackson Laboratories) were used 
at 1:10,000 diluted in 5% milk in TS-T. Immunoblot analysis was performed 
using either an enzyme-linked chemiluminesence substrate (Luminata 
Crescendo Western HRP Substrate, EMD Millipore) and developed with 
film or IR Dye-labeled secondary antibodies (anti rabbit IgG IRDye 800, LI-
COR 926-32211) and imaged using the Odyssey infrared imager (LI-COR). 
Images were processed with Adobe Photoshop CS6. 
 For SAC co-localization studies using immunofluorescence 
microscopy, cells were treated with siRNA to SENP1 for 48 hours on glass 
coverslips. Cells were fixed in 3.5% paraformaldehyde in PBS for 7 min and 
permeabilized in 0.5% Triton-X 100 in PBS for 20 min at room temperature. 
For GFP-SENP1 and SAC localization studies, cells were permeabilized 
using transport buffer (200 mM HEPES pH 6.5, 110 mM potassium acetate, 
20 mM magnesium acetate, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 20 
µg/mL aprotinin, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 20 mM 
N-ethylmaleimide (NEM), and 20 µg/mL digitonin at room temperature for 
15 min. Cells were then washed 1x with PBS, and fixed in 2% formaldehyde 
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at room temperature for 20 mins. After washing with PBS, cells were 
immunostained at room temperature using respective antibodies. 
 Immunostaining was performed with the following antibodies diluted 
in PBS supplemented with 2% BSA: 414 (mouse, 1:2000), BubR1 (rabbit, 
GeneTex, 1:500), Cdc20 (mouse, p55 CDC(E-7): sc13-162, 1:50), CREST 
(human, 15-235-0001, Antibodies Inc., 1:100), Hec1 (mouse, BD 
Transduction 611040, 1:100) Mad1 (mouse, 1:500, Active Motif), followed 
by secondary antibodies to Alexa Fluor 594 and Alexa Fluor 647 (1:300, 
Life Technologies, Grand Island, NY). Images were acquired using a Zeiss 
Observer Z1 fluorescence microscope with a Zeiss Plan-Apochromat 63x 
objective (numerical aperture 1.40) and Apotome VH optical sectioning grid 
(Carl Zeiss, Jena, Germany). Images were obtained at room temperature 
with immersion oil using a Zeiss AxioCam MRm camera and processed 
using AxioVision Software Release 4.8.2 and Adobe Photoshop CS6. 
 
Fixed and live cell timelapse microscopy 
 Fixed images were acquired using a Zeiss Observer Z1 fluorescence 
microscope with a Zeiss Plan-Apochromat 63x objective (numerical aperture 
1.40) and Apotome VH optical sectioning grid (Carl Zeiss, Jena, Germany). 
Images were obtained at room temperature with immersion oil using a Zeiss 
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AxioCam MRm camera and processed using AxioVision Software Release 
4.8.2 and Adobe Photoshop CS6. 
 For live-cell imaging, cells were cultured in Lab-Tek Chambered #1.0 
Borosilicate Coverglass slides (Nunc, Rochester, NY), doxycycline induced 
and siRNA treated targeting APC4, and then imaged 48 hours post-
transfection. Immediately before imaging, cells were switched to pre-
warmed CO2-independent media (Invitrogen) supplemented with 10% FBS. 
Cells were maintained at 37°C on a Zeiss Observer Z1 fluorescence 
microscope fitted with an incubation chamber. Images were acquired using a 
Zeiss EC Plan-Neofluor 40x objective (numerical aperture 1.3) every 5 min 
for 16 hours (unless otherwise indicated) with a Zeiss AxioCam MRm 
camera and processed using AxioVision Software Release 4.8.2. Data 




Statistical analyses were carried out using Prism 6 for Mac OSX (GraphPad 
Software, Inc.) with two-tailed student t tests. Data with a P-value < 0.05 




SENP1 activity is required for appropriate timing of the metaphase-
anaphase transition  
We previously reported that SENP1 is critical for normal progression 
through mitosis20, but its precise molecular functions are not understood. To 
more precisely characterize the requirements of SENP1 during mitosis, 
HeLa cells expressing yellow fluorescent protein (YFP)-tagged histone H2B 
were used to facilitate live cell imaging. Cells depleted of SENP1 by siRNA 
for 48 hours were analyzed by timelapse microscopy, which revealed no 
defects in the timing of nuclear envelope breakdown (NEBD) to metaphase 
plate alignment compared to control cells (Figure 3-1A-C). On average, 
control cells spent ~35 minutes while siSENP1 cells spent ~29 minutes 
transitioning from NEBD-metaphase. In contrast, there was a statistically 
significant difference in the transition time between metaphase plate 
alignment and anaphase onset in control cells (~26 minutes) compared to 
siSENP1 cells (~70 minutes) (Figure 3-1D). Fixed images from timelapse 
analysis, with time indicated in minutes, show that the prolonged metaphase-
anaphase transition observed in SENP1-depleted cells occurs without 
spindle fatigue or the generation of chromosomal bridges (Figure 3-1A-B). 
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These observations confirm a critical role for SENP1 during the metaphase-
anaphase transition. 
 Anaphase onset and mitotic exit is dependent on APC/C activity 
towards specific protein substrates, including securin and Cyclin B1. To 
evaluate the activity of APC/C under conditions of SENP1 depletion, we 
analyzed the rate of Cyclin B1 degradation. Cells were treated with control 
or SENP1 targeting siRNA oligos, synchronized in S-phase using a double 
thymidine block, and released into drug-free medium. Cell lysates were 
collected at varying timepoints after release and immunoblotting showed 
that Cyclin B1 degradation was attenuated in SENP1-depleted cells 
compared to control cells (Figure 3-1E-F). Immunoblots to SENP1 show 
protein depletion in cells treated with siRNA across all timepoints, and 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as a loading 
control. The observation that Cyclin B1 degradation is delayed is consistent 
with the observed mitotic delay and suggests a role for SENP1 in regulating 
processes that control the metaphase-anaphase transition. 
 
SENP1 depletion does not affect kinetochore-microtubule attachments 
or perturb SAC signaling 
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 Stable, amphitelic attachments between the kinetochores of sister 
chromatids and the mitotic spindle are required for chromosome alignment, 
silencing of the SAC and promotion of timely anaphase onset. To investigate 
the possibility that SENP1 activity is required during early stages of mitotic 
chromosome capture and alignment, we evaluated the formation of the 
bipolar spindle, tension between kinetochores of metaphase aligned sister 
chromatids, and SAC signaling. Cells were treated with control or SENP1 
siRNAs for 48 hours, fixed and co-stained with CREST to identify 
centromeres and tubulin to mark the mitotic spindle, and analyzed by 
immunofluorescence microscopy (Figure 3-2A). During metaphase, control 
and SENP1-depleted cells both form normal amphitelic attachments between 
the mitotic spindle and kinetochores of sister chromatids. To determine if 
SENP1 depletion affects tension between kinetochores of metaphase aligned 
sister chromatids, inter-kinetochore distances were measured (Figure 3-2B). 
On average, control and SENP1-depleted cells had indistinguishable inter-
kinetochore distances, measuring ~0.78-0.79 µm. These findings are 
consistent with timelapse analysis, whereby early mitotic events leading up 
to metaphase are indistinguishable between control and SENP1-depleted 
cells. Immunoblots with antibodies specific for SENP1 show protein 
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depletion in cells treated with siRNA, and tubulin was used as a loading 
control (Figure 3-2C). 
 To evaluate the inhibitory signals generated at prometaphase 
kinetochores, we evaluated SAC proteins in control and SENP1-depleted 
cells. Immunofluorescence microscopy analysis was performed using 
antibodies specific for Cdc20, Mad1, BubR1. Cells were co-stained with 
anti-CREST antibodies to indicate centromeres. At early prometaphase, 
localization of SAC proteins at unattached kinetochores was robust in both 
control and siSENP1 treated cells (Figure 3-2D). Upon metaphase plate 
alignment, SAC proteins are appropriately released, as fluorescence levels at 
kinetochores dissipated similarly in both control and siSENP1 treated cells. 
These data demonstrate that the recruitment and release of SAC proteins at 
the kinetochore is not affected by SENP1 depletion. 
 To address whether higher levels of SAC proteins accumulate at 
kinetochores in SENP1-depleted cells during prometaphase, cells were 
treated with control or siSENP1 for 48 hours and treated with nocodazole 
(Figure 3-3). Analysis of Mad1, Mad2, BubR1, and Bub1 levels at 
kinetochores showed no apparent differences in SENP1-depleted cells 
compared to control cells. Thus, relative levels and localization of 
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checkpoint proteins at kinetochores are not affected in SENP1-depleted 
cells. 
 
SAC inactivation partially rescues the metaphase-anaphase delay in 
SENP1-depleted cells 
 To address whether SENP1 activity is required downstream of SAC 
silencing, we treated control and SENP1-depleted cells (Figure 3-4) with the 
Mps1 kinase inhibitor, reversine45. Progression through mitosis, beginning 
with nuclear envelope breakdown (NEBD) to anaphase onset was monitored 
in control or siSENP1 cells for 48 hours followed by 4 hours of timelapse 
imaging. Immunoblots with antibodies specific to SENP1 and GAPDH as a 
loading control indicated effective protein depletion following knockdown 
(Figure 3-4A). Control cells spent ~47 minutes on average in mitosis, while 
reversine treatment shortened the mitotic duration to ~17 minutes (Figure 3-
4B). In contrast, SENP1-depleted cells spent ~105 minutes on average in 
mitosis and reversine treatment shortened this to ~33 minutes (Figure 3-4B). 
Fixed images from timelapse acquisition depict random chromosome 
segregation and catastrophic mitotic exit in control cells treated with 
reversine (Figure 3-4C). Chromosomes in cells depleted of SENP1, 
however, align at the metaphase plate just prior to an apparently normal 
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mitotic exit (Figure 3-8D). These results suggest either incomplete SAC 
silencing in SENP1-depleted cells or a role for SENP1 downstream of 
checkpoint inactivation.  
 
SENP1 depletion effects are not dependent on APC/C sumoylation 
 A regulatory role for sumoylation of APC4 in activation of APC/C 
and timely mitotic exit was reported in Chapter 2. To determine if the 
metaphase-anaphase delay observed in SENP1-depleted cells involves 
enhanced sumoylation of APC4, we analyzed APC4 (wild type) and 
APC4KR (sumoylation mutant) cells treated with siSENP1 by timelapse 
microscopy (Figure 3-5). As expected, cells expressing APC4 and treated 
with siSENP1 exhibited a prolonged metaphase-anaphase transition (~79 
min). Furthermore, cells expressing APC4KR and treated with siSENP1 
exhibited a similar metaphase-anaphase delay (~81 min), which was 
significantly greater than the delay in control APC4KR cells (~65.00 min). 
Thus, the effect of SENP1 depletion on the metaphase-anaphase transition is 
not dependent on enhanced sumoylation of APC4.  
 
SENP1 depletion affects Mad1 and Mad 2 accumulation at NPCs during 
interphase 
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 Recent work has demonstrated that pre-assembly of SAC proteins at 
NPCs during interphase contributes to the total pool of checkpoint proteins 
present in mitosis and is critical for appropriate mitotic timing and genome 
maintenance12,46. To determine if SENP1 depletion affects recruitment of 
Mad1 and Mad2 to NPCs during interphase, we analyzed cells by 
immunofluorescence microscopy (Figure 3-6A). Mad1 levels at NPCs were 
significantly elevated in SENP1-depleted cells, with an average fluorescence 
intensity of ~4.8 (units/pixels2) compared to 3.9 in control cells (Figure 3-
6B). Similarly, levels of Mad2 were also significantly higher at NPCs in 
SENP1-depleted cells compared to control cells, with fluorescence 
intensities of ~6.8 and (units/pixels2) ~5.5, respectively (Figure 3-6C). These 
findings suggest that excess assembly of SAC complexes at NPCs during 
interphase may contribute to the metaphase-anaphase delay observed in 
SENP1-depleted cells.  
 
Characterization of determinants of SENP1 localization during 
different stages of the cell cycle  
 Based on the finding that Mad1 and Mad2 accumulate at higher levels 
at NPCs in SENP1 depleted cells, we next analyzed SENP1 targeting signals 
in SENP1 and interactions with specific NPC subdomains. We previously 
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demonstrated that SENP1 localizes to NPCs during interphase and to 
centrosomes, the mitotic spindle, and kinetochores during metaphase37,39 
(Figure 3-7). SENP1 contains a nuclear localization signal (NLS) at amino 
acids 170-177 and a C-terminal nuclear export signal at amino acids xyz 
(Figure 3-7A)47. Other signals affecting SENP1 localization, however, have 
not been defined. To further characterize the sequence elements that direct 
NPC targeting, GFP-SENP1 N-terminal fragments (Figure 3-8A) were 
expressed in HeLa cells and co-localization with mAb 414 (an NPC marker) 
was analyzed by immunofluorescence microscopy (Figure 3-8B). Full-
length SENP1, and fragments spanning amino acids 154-272 and 273-449 
co-localized with NPCs, while fragments spanning amino acids 1-40 and 41-
153 localized to the nucleus (Figure 3-8B). These findings reveal two 
independent NPC-targeting signals in the SENP1 N-terminus, as well as 
previously unrecognized NLSs within the first 153 amino acids.  
To identify signals in SENP1 that direct localization during each stage 
of mitosis, we expressed GFP-tagged SENP1 and varying SENP1 fragments 
in HeLa cells and analyzed co-localization with kinetochore (anti-Hec1), 
centromere (anti-CREST), and centrosome (anti-centrin) markers by 
immunofluorescene microscopy. Full-length SENP1 showed co-localization 
with Hec1 during prometaphase, indicating kinetochore recruitment in early 
 164
stages of mitosis (Figure 3-9). Consistent with previous findings, full-length 
SENP1 also localized to centrosomes, kinetochores, and the mitotic spindle 
during metaphase. GFP-tagged SENP1 fragments 1-41 and 41-153 localized 
to the mitotic spindle and retained some kinetochore localization, while 154-
272 did not localize to mitotic structures (Figure 3-9). Notably, the 273-449 
fragment localized to the centromeres, mitotic spindle, and retained some 
kinetochore localization, albeit to a lesser extent compared to full-length 
SENP1. Like NPC targeting, these findings demonstrate the contributions of 
multiple N-terminal domains in localizing SENP1 to mitotic structures. 
 
BioID analysis demonstrates unique NPC interactions with distinct 
SENP1 N-terminal domains  
 To assess the interactions of SENP1 with subunits of the NPC, we 
used the proximity-dependent biotin identification, or BioID, technique 
essentially as previously described48 (Figure 3-10A). In brief, a Flag-BirA*-
SENP1 fusion protein was inducibly expressed in HeLa cells. BirA* is a 
biotin conjugating enzyme mutant (BirA R118G) which facilitates the 
efficient biotinylation of lysine residues in close proximity. Proteins 
biotinylated by Flag-BirA*-SENP1 were affinity purified using streptavidin 
and identified using mass spectrometry. Proteins including karyopherins, 
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nucleoporins, and nuclear lamins were identified (Table 3-1). These data are 
consistent with the steady state concentration of SENP1 at NPCs20. N-
terminal fragments of SENP1 were also subjected to BioID analysis. 
Consistent with the findings that GFP-SENP11-41 and GFP-SENP141-153 did 
not localize to NPCs (Figure 3-10B), no interactions with nucleoporins were 
detected with these fragments (Table 3-1). Average spectral counts indicated 
that full-length SENP1 and fragments 153-272 and 273-449 all interacted 
with nucleoporins, including the Nup107 complex and Tpr. Interestingly, the 
153-272 fragment showed higher than average spectral counts for the 
Nup107 complex while the 273-449 fragment showed higher than average 
spectral counts for Tpr, a component of the nuclear basket. Analysis of GFP-
SENP1 and GFP-SENP1273-449 by fluorescence microscopy showed co-
localization with Tpr, consistent with the BioID results (Figure 3-10C). 
Taken together, these data confirm that sequence elements in the N-terminus 
of SENP1 specify NPC targeting and demonstrate unique interactions with 
distinct components of the NPC.  
 
NPC targeting domains of SENP1 are critical for functions in mitosis 
 To determine if interactions with specific subunits of the NPC are 
critical for SENP1 function, we generated stable inducible cell lines for 
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expression of mCherry-tagged SENP1 and SENP1 deletion mutants (Figure 
3-11A).  
Specifically, mCherry was fused to a truncated SENP1 missing the first 153 
amino acids (D153), which we predict maintains interactions with the 
Nup107 complex and Tpr, while a truncation of the first 272 amino acids 
(D272) maintains interactions with Tpr only. To ensure that the truncation 
mutants did not affect catalytic activity towards SUMO modified substrates, 
mCherry-SENP1 fragments were transfected into cells together with Myc-
tagged SUMO2, and the effects on SUMO conjugation were analyzed by 
immunoblot analysis (Figure 3-11B-C). Expression of mCherry SENP1 full 
length (FL), D153 and D272 all caused global decreases in high molecular 
weight SUMO2 conjugates, while an mCherry empty vector and a catalytic 
mutant SENP1C603S do not (Figure 3-11B-C).  
The localization of individual truncation mutants was also analyzed 
by fluorescence microscopy. Consistent with localization studies of GFP-
SENP1 fusions, mCherry-SENP1 and SENP1C603S were targeted to the NPCs 
during interphase, and re-localized to centrosomes, the mitotic spindle, and 
kinetochores during metaphase (Figure 3-11D-E). mCherry-SENP1D153 and 
mCherry-SENP1D272 also retained NPC localization during interphase, and 
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limited localization at the centrosomes, the mitotic spindle, and kinetochores 
during metaphase.  
 To evaluate the functional requirements of SENP1 N-terminal 
domains for appropriate mitotic progression, we performed rescue 
experiments using these stable, inducible cell lines. Cells were depleted of 
endogenous SENP1 for 48 hours with concomitant doxycycline-induced 
mCherry-SENP1 expression (Figure 3-12A, B). As expected, siSENP1 cells 
exhibited a prolonged metaphase-anaphase delay compared to control cells 
(Figure 3-12C-D, fixed images with time indicated in minutes, E-F). 
Expression of full-length, wild type mCherry-SENP1 rescued the 
metaphase-anaphase delay, while mCherry-SENP1C603S did not (Figure 3-
12C-D, G-H).  Importantly, expression of mCherry-SENP1D153 also rescued 
the metaphase-anaphase delay caused by SENP1 depletion, whereas 
expression of mCherry-SENP1D272 did not. Thus, our findings reveal that the 
first 153 amino acids of SENP1 are dispensable for normal metaphase-
anaphase transitions, whereas residues from 153-272, which mediate 





 During different stages of the cell cycle, proteins in the SUMO 
pathway localize to unique sub-cellular compartments, with distinct 
regulatory roles. Over the past several decades, molecular mechanisms by 
which SUMO modification coordinates cellular processes have been 
revealed. Functional roles for SUMO deconjugating enzymes, or SENPs, in 
human cells are diverse and are involved in almost every essential cellular 
process. SUMO modification of transcription factors has broadly been 
characterized as inactivating, while de-conjugation by SENP1 have been 
implicated in activating transcription of innate immune response elements49. 
Additional roles for SENP3 and SENP5 in regulating ribosome biogenesis, 
SENP6 editing SUMO-ubiquitin hybrid chains, and SENP7 in chromatin 
remodeling, all indicate an axis of regulation as diverse as SUMO 
conjugation. Roles for SENPs have also been characterized for mitotic 
progression, as overexpression of SENP2 causes defects in kinetochore 
targeting, resulting in chromosome congression defects50 while SENP6 
regulates the assembly of inner kinetochore proteins51. Here we further 
describe a functional requirement of N-terminal SENP1 interactions with 
components of the NPC that coordinate mitotic checkpoint signaling, to 
properly coordinate the timing of metaphase to anaphase transitions. 
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 We have expanded our investigation on the functional role of SENP1 
during mitosis20. Analysis of kinetochore-microtubule interactions in SENP1 
depleted cells does not affect SAC recruitment during prometaphase nor 
release during metaphase from the kinetochore. Inactivation of the SAC by 
reversine treatment largely rescues the metaphase-anaphase delay observed 
in SENP1 depleted cells, implicating a functional role for SENP1 in 
regulating checkpoint signaling. Notably, siSENP1 cells treated with 
reversine form a metaphase plate and undergo a more normal mitotic 
progression, with no statistically significant differences in mitotic timing 
compared to control cells (p = 0.095, Figure 3-8D). The absence of 
catastrophic anaphases in siSENP1 cells is also noted, in addition to the 
relatively normal mitosis under a condition where SAC is chemically 
inhibited. This may be due to incomplete SAC silencing by reversine 
treatment, and while many of the signaling and mechanistic processes of the 
SAC at the kinetochore have been characterized, it is yet unknown how the 
“rheostat52” of checkpoint signaling is controlled. SENP1 activity may be 
involved in the fine-tuning process of the “rheostat” and likely affects the 
activity of a variety of substrates that have potentially opposing roles during 
mitotic progression. 
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 Here we demonstrate that SENP1 depletion affects targeting and 
accumulation of Mad1 and Mad2 at the NPCs during interphase. Pre-
assembly of SAC complexes during interphase contribute towards inhibitory 
signals against the APC/C, and increased steady state levels of SAC proteins 
can contribute towards delayed metaphase-anaphase timing. Whether a 
soluble fraction of SAC proteins that does not localize at the kinetochore 
contributes towards inhibiting APC/C activity is yet unknown. SENP1 
depletion, resulting in hyper-sumoylation of substrates, may function to 
recruit or retain Mad1 and Mad2 at the nuclear pore complexes. Indeed, 
Mad1 has been identified as a SUMO substrate in proteomic studies but has 
yet to be validated36. Whether SENP1 is a regulator of Mad1 SUMO 
modification, or if novel SUMO-SIM interactions function to retain Mad1 at 
the nuclear pores are questions of particular future interest. While SENP1 
and SENP2 have been previously implicated in regulating the interaction 
between Mad1 and Mad2 with Tpr11, neither have been validated as SUMO 
substrates. Further analysis of the relationship between these proteins will 
elucidate mechanistic roles for SUMO-mediated checkpoint pre-assembly at 
the NPC. Whether the pre-assembled checkpoint complexes contribute to 
inhibitory APC/C signaling localized at kinetochores, or if a soluble 
kinetochore-independent fraction of inhibitory MCCs are generated to 
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attenuate APC/C activity, and whether one pool is under regulatory control 
by SENP1 are all outstanding questions to pursue.  
 
 We also performed localization studies using GFP-SENP1 constructs 
containing N-terminal truncations. Consistent with a previously 
characterized nuclear localization signal (NLS) at amino acids 171-7, full 
length SENP1 and truncation mutants containing this NLS localize to the 
nucleus47. Based on our analysis, additional sequences within the first 153 
amino acids may be responsible for nuclear targeting of GFP-SENP11-40 and 
GFP-SENP141-153. Localization analysis was also performed on mitotic cells 
for GFP-SENP1 and N-terminal truncation mutants. Targeting to the mitotic 
spindle is conferred by sequences in SENP1 spanning amino acids 1-40, 41-
153, and 273-449, while full length GFP-SENP1 also localizes to the 
centrosomes and at kinetochores. How SENP1 is recruited to these mitotic 
structures is an area of key interest, as it is yet unknown if SENP1 interacts 
with specific proteins at the kinetochore. Another possibility for SENP1 
targeting is mediated by putative SIM regions in the N-terminus of SENP1 
which may direct SENP1 recruitment to SUMO modified substrates at 
mitotic structures. Whether SENP1 activity is under control of other post-
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translational modifications such as phosphorylation to direct specific sub-
cellular targeting is also an outstanding question.  
 In an unbiased approach towards identifying SENP1 interacting 
proteins in asynchronous cells, we used BioID, a method with sensitivity in 
capturing non-covalent interactions. Among the categories of proteins 
interacting with SENP1 are karyopherins, the Nup107-160 complex, FG 
repeat nucleoporins, and the nuclear lamina. During interphase, two separate 
targeting domains to NPCs are featured in the N-terminus of SENP1, 
spanning amino acid residues 153-272 and 273-449. BioID analysis 
indicates that these domains interact with the nucleoporins Nup107 and Tpr, 
respectively. Consistent with this finding, other N-terminal fragments that 
are not targeted to the pore (spanning amino acid residues 1-41 and 41-153) 
were not identified through BioID analysis (Table 3-1). The association of 
SENP1153-272 with the Nup107 complex together with the interaction of 
SENP1273-449 with Tpr are particularly interesting, as these nucleoporins are 
known to regulate kinetochore assembly and signaling during mitosis. It is 
yet unknown how SENP1 interacts with these nucleoporins. Whether the 
nucleoporins or other binding partners, like Mad1, are SUMO modified – 
will be an important mechanistic question to address. Furthermore, analysis 
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using the BirA*-SENP1 system with mitotic cells may reveal additional 
information regarding unique interactions.  
 Finally, to investigate the functional requirements of N-terminal 
sequence domains in SENP1, we generated a system whereby endogenous 
depletion of SENP1 could be complemented by the expression of inducible 
transgenes of full length, catalytically mutant (C603S), or N-terminal 
truncations of SENP1. Endogenous depletion of SENP1 and expression of 
mCherry SENP1 functionally rescues the metaphase-anaphase delay, while 
mCherry SENP1C603S does not. This assay was used to evaluate if binding 
interactions with either the Nup107 complex or Tpr is required for normal 
mitotic progression. Expression of mCherry SENP1 variants and analysis by 
timelapse microscopy revealed a functional rescue of the metaphase-
anaphase delay in mCherry SENP1D153 which binds to the Nup107 complex. 
Interestingly, mCherry SENP1D272, which binds to Tpr but not Nup107, does 
not rescue the metaphase-anaphase delay observed in SENP1 depleted cells. 
Taken together, these data suggest that SENP1 interactions with Nup107 are 
critical for normal metaphase-anaphase transition times.  
 Recent advances in high throughput studies revealing the SUMO 
proteome have identified thousands of additional proteins that are under 
regulatory control by the SUMO pathway36–38,53,54. Validation and 
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characterization of these proteins, in addition to proteomic analyses of 
SENP1 and other SENP isoforms, will further demonstrate the versatility of 
SUMO modification in regulating mitotic progression. Finally, chemical 
inhibitors of the SUMO pathway55,56 have been an area of developing 
attention. Future work towards the development of specific inhibitors 
towards individual SENPs will facilitate novel discoveries on how the 
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SENP1 is required for normal metaphase-anaphase transition timing. 
 
(A) Cells were treated with control or siRNA to APC4 for 48 hours were 
imaged by timelapse live cell acquisition for 16 hours. Fixed images from 
timelapse acquisition of control cells entering mitosis beginning with NEBD 
at 0:00 (hr:min). (B) siSENP1 cells delay metaphase-anaphase transitions; 
fixed images from timelapse aquisition. (C) Analysis represents mitotic 
progression time in minutes, beginning with nuclear envelop breakdown 
(NEBD) to metaphase, and metaphase to anaphase onset. Data shown are 
from three replicate experiments. Control and siSENP1 cells spent similar 
times on average from NEBD to metaphase. (Control 23.86 min ± 0.55, 
n=140; siSENP1 25.50 min ± 1.18; n=140; average ± SD). (D) siSENP1 
cells have a prolonged metaphase-anaphase transition time. (Control, 29.00 
± 0.79 min, n = 140; siSENP170.14 ± 3.71, n=140; average ± SD, 
P<0.0001). (E-F) Cells were treated with control or siSENP1 for 48 hours, 
followed by a double thymidine block and release into drug-free media. 
Cells were collected at various timepoints following release and 
immunoblotting to Cyclin B1, glyceraldehyde-3-phosphate dehydrogenase 








SENP1 depletion does not affect inter-kinetochore distances or SAC 
protein signaling. 
(A) Cells were treated with control or siSENP1 for 48 hours before fixation 
and immunofluorescence to CREST (red) and tubulin (green) and 
counterstained with DAPI. Bar, 2 µm. (B) Inter-kinetochore distances were 
determined (control 0.78 µm ± 0.21, n=463; siSENP1 0.79 µm ± 0.25, 
n=577. P=0.87). (C) Immunoblots from control or siSENP1 cells with 
antibodies specific for SENP1 and tubulin as a loading control. (D) Cells 
were treated with control or siSENP1 for 48 hours before fixation and 
immunofluorescence to SAC proteins Cdc20, Mad1, and BubR1 (green) 
with co-immunostaining with CREST (red) and chromatin/DNA 
counterstained with DAPI. Representative prometaphase and metaphase 









SENP1 depleted cells properly localize SAC proteins during 
prometaphase. 
Cells were treated with control or siSENP1 for 48 hours and treated for 12 
hours with nocodazole to arrest in prometaphase prior to fixation and 
immunofluorescence analysis. Antibodies specific to (A) Mad1(B) BubR1 
(C) Mad2 or (D) Bub1 used in addition to co-staining with CREST to 






Reversine treatment causes catastrophic anaphase in control cells but 
rescues the metaphase-anaphase delay in SENP1 depleted cells. 
(A) HeLa cells were treated with control or siSENP1 for 48 hours. 
Immunoblotting to SENP1 and GAPDH. (B) siSENP1 cells spent longer 
total times in mitosis. (control, 46.53 min ± 28.89, n = 17; siSENP1 104.61 
± 37.30, n=31; average ± SD, P=0.095). Control cells treated with reversine 
spent shorter total times in mitosis compared to control cells. (Control, 46.53 
min ± 28.89, n = 17; control + Reversine 17.47 ± 10.75, n=34; average ± 
SD, P=0.0008). siSENP1 cells treated with reversine spent shorter total 
times in mitosis compared to siSENP1 cells. (siSENP1 104.61 ± 37.30, 
n=31; siSENP1 + Reversine 33.45 ± 20.55, n=64; average ± SD, P<0.0001). 
(C) Fixed images from timelapse microscopy analysis of control cells treated 
with reversine (time in hr:min). (D) Fixed images from timelapse 





























SENP1 depletion in APC4 and APC4KR cells. 
 
(A) APC4 and APC4KR (SUMO mutant) cells, previously shown to limit the 
activity of the APC/C were treated with siRNA targeting oligonucleotides to 
deplete endogenous APC4 with concomitant doxycycline-induced transgene 
expression. Cells were co-depleted of SENP1. Timelapse imaging analysis 
shows NEBD-metaphase timing in APC4 + siSENP1, APC4KR, and APC4KR 
+ SENP1 cells (33.24 min ± 1.35, 35.92 min ±1.21, and 34.43 ± 1.41, 
respectively) and also metaphase-anaphase timing in APC4 + siSENP1, 
APC4KR, and APC4KR + SENP1 cells (79.49 min ± 4.51, 65.00 min ± 4.72, 
and 80.67 min ± 3.73, respectively). P-values from two-tailed t-tests are 
shown. (B) Fixed images from timelapse analysis are shown in hr:min for 

















SENP1 depletion results in accumulation of Mad1 and Mad2 at the 
nuclear pores during interphase. 
(A) Cells were treated with control or siSENP1 for 48 hours before fixation 
and immunofluorescence to Mad1 or Mad2 (green) and chromatin/DNA was 
counterstained with DAPI. (B) Relative fluorescence density for Mad1 was 
quantified and normalized to the area of the nuclear periphery in cells treated 
with a control siRNA or targeting SENP1. Control cells have a relative 
fluorescence intensity of 3.95 ± 0.52 (n=18) compared to siSENP1 cells 4.86 
±  0.77 (n=20) (P=0.00013). (C) Relative fluorescence intensity for Mad2 
was quantified and normalized to the area at the nuclear periphery in cells 
treated with a control siRNA or targeting SENP1. Control cells have a 
relative fluorescence intensity of 5.46 ±  1.22 (units/pixel2) (n=19) compared 
to siSENP1 cells 6.83 ±  1.69 (n=20) (P=0.0064). (D) Immunoblot of control 













GFP-SENP1 localizes to unique sub-cellular compartments during the 
cell cycle. 
Asynchronous HeLa cells were transfected with GFP-SENP1 for 48 hours. 
Immunofluorescence with Hec1 antibody and nuclei/chromosomes 













SENP1 N-terminal domains localize to the nuclear pore. 
 
(A) SENP1 is a 644 amino acid protein, with a nuclear localization signal 
sequence (NLS) at amino acids 171-177, a conserved catalytic domain 
spanning amino acids 419-644, a catalytic cysteine at 603, and a nuclear 
export signal sequence (NES) at amino acids 633-644. N-terminal GFP 
fusion constructs were generated for SENP1 1-40, 41-153, 154-272, and 
amino acids 273-449. (B) GFP-SENP1 constructs were transfected into 
HeLa cells. Immunofluorescence analysis with the nuclear pore complex 
marker 414 and counterstaining of chromosomes/DNA with DAPI is shown 







SENP1 and SENP1 N-terminal domains localize to kinetochores, 
centromeres, and the mitotic spindle during metaphase. 
GFP-SENP1 and various GFP-SENP1 N-terminal truncation constructs were 
transfected into HeLa cells and analyzed by immunofluorescence with 
antibodies to (A) centromeres (CEN, red) and (B) kinetochores (CREST, 






BirA-SENP1 mass spectrometry analysis reveals unique interactions of 
SENP1 and SENP1 N-terminal fragments with nucleoporins. 
(A) An N-terminal fusion of Flag-BirA with SENP1 was generated and 
incubated with biotin ligase and HeLa cell lysates. Interactions with the 
nuclear pore complex were among the substrates identified. Nup160, 
Nup107-133, Nup153, and Tpr are nucleoporins that compose the nuclear 
pore complex. Tpr comprises the nuclear basket which resides on the 
nucleoplasmic face of the pore.  (B) Average pectral counts from BirA-
SENP1 analysis is shown. GFP-SENP1 full length, GFP-SENP1153-272, and 
GFP-SENP1273-449 were used. Gradient grey colors indicate increased 
frequency of spectra. (C) Cells were transfected with GFP-SENP1 full 
length and GFP-SENP1273-449. Immunofluorescence analysis shows co-











mCherry SENP1 constructs are catalytically active towards 
deconjugating SUMO substrates and localize to unique sub-cellular 
compartments. 
(A) Stable inducible cell lines expressing an N-terminal mCherry fusion to 
SENP1 full length (mCherry SENP1 FL), SENP1 full length catalytic 
mutant (mCherry SENP1C603S), and N-terminal truncations (mCherry 
SENP1D153 and mCherry SENP1D272) were generated in YFP-H2B HeLa 
cells. A Nup107 binding domain (amino acids 153-272) and a Tpr binding 
domain (amino acids 273-449) are indicated. (B) Cells expressing mCherry 
or mCherry SENP1, or mCherry SENP1 fragments were transfected with 
myc-SUMO2 to determine catalytic activity. Cell lysates were subjected to 
immunoblot analysis with antibodies for mCherry and Myc. A non-specific 
background band migrates at ~57 kDa using the Myc antibody. (D) YFP-
H2B HeLa cells with induced expression of mCherry SENP1 FL (E) 
mCherry SENP1C603S (F) mCherry SENP1D153 and (G) mCherry SENP1D272 
























Figure 3-12  
mCherry SENP1 rescues SENP1 depletion phenotype, N-terminal 
SENP1 is functionally required for normal metaphase-anaphase 
transition timing. 
(A) Stable inducible HeLa cell lines expressing a constitutive yellow 
fluorescence protein fused to histone H2B (YFP-H2B) were depleted of 
endogenous SENP1 by siRNA for 48 hours with (B) concomitant 
doxycycline induced expression of mCherry SENP1 FL, mCherry 
SENP1C603S, mCherry SENP1D153 and mCherry SENP1D272 for 48 hours. (C) 
Total time in mitosis, beginning with nuclear envelope breakdown (NEBD) 
to metaphase and anaphase was analyzed from three independent replicates 
of timelapse imaging analysis. Control and siSENP1 cells transition from 
NEBD-metaphase in 27.29 min ± 0.76 and 30.03 min ± 1.16, respectively 
(average ± SD, n=60). Cells depleted of SENP1 and induced expression of 
mCherry SENP1 WT, mCherry SENP1C603S, mCherry SENP1D153 and 
mCherry SENP1D272 transition from NEBD-metaphase in 27.25 min ± 2.75, 
36.49 min ± 2.92, 39.71 min ± 2.03, and 32.28 min ± 2.31, respectively 
(average ± SD, n=42). (D) Time between metaphase-anaphase was analyzed. 
Control and siSENP1 cells transition from metaphase-anaphase in 26.14 min 
± 2.78 and 76.39 min ± 4.24, respectively (average ± SD). Cells depleted of 
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SENP1 and induced expression of mCherry SENP1 WT, mCherry 
SENP1C603S, mCherry SENP1D153 and mCherry SENP1D272 transition from 
NEBD-metaphase in 35.75 min ± 4.75, 87.44 min ± 14.34, 38.93 min ± 
















Average spectral counts from Flag-BirA-SENP1 proteomic study 
 
 





Karyopherins KPNB1 77 23 37 52 32 KPNA2 24     14 11 
              
Nup107-160 NUP133 40     204   NUP107 27     119   
              
FG Nups 
RANBP2 130 20 79 85 44 
NUP153 176   29 155 130 
NUP50 71     25 34 
NUP155 16     12   
NUP98 17     61   
            
AHCTF1 121     62 45 
POM121C 19     34   
              
Nuclear 

















METHODS TO INVESTIGATE  





 We have identified and validated that a subunit of the Anaphase 
Promoting Complex/Cyclosome (APC/C)—a key regulator of mitotic exit—
is SUMO modified during mitosis. To further characterize the functional 
consequence of APC4 SUMO modification, several approaches were 
utilized. Through our studies, we confirmed that APC4 sumoylation occurs 
during mitosis and can be readily SUMO modified using a variety of in vitro 
and in vivo approaches. Here, we describe methods used to induce APC4 
SUMO modification and conclude with observations regarding the 
potentially distinct substrates SUMO modified APC4 interacts with.  
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SENP1 depletion results in enhanced APC4 SUMO modification 
 We previously observed that APC4 SUMO modification is under the 
regulatory control of the SUMO isopeptidase SENP1 (Figure 3-2D). To 
determine the temporal regulation of APC4 SUMO modification during the 
mitotic stage of the cell cycle, HeLa cells were treated with a control or 
SENP1 targeting siRNA oligo for 48 hours, followed by a double thymidine 
block (19 hours in 2 mM thymidine, 6-hour release into drug free media, 
followed by 19 hours in 2 mM thymidine) to synchronize cells into S phase. 
Following release into drug-free media, control cells resume cell cycle 
progression and enter mitosis around 8-10 hours following release, as 
indicated by immunoblotting to mitotic markers, Cyclin B1 and 
phosphorylated histone H3 (PH3). Antibodies specific for SENP1 were used 
to demonstrate protein depletion in siSENP1 cells during the timecourse 
analysis, and antibodies to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as a loading control (Figure A-1). Notably, APC4 
sumoylation levels are higher in cells treated with siSENP1, as indicated by 
arrows. In control cells, mitotic exit as indicated by decreased Cyclin B1 
levels occurs within 12 hours of thymidine release. However, SENP1 
depleted cells demonstrate a prolonged mitotic timing, and Cyclin B1 levels 
are depleted ~22 hours following double thymidine release. These data 
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suggested that SENP1 depletion, resulting in hyper-sumoylated APC4, may 
have an effect on mitotic exit. However, we later discovered that constitutive 
SUMO modification of APC4 did not cause metaphase delays (Figure 3-7). 
Thus, we conclude that although APC4 is hyper-sumoylated, APC4 is not 
the molecular target that is responsible for the metaphase-anaphase delay 
observed in SENP1 knockdown. 
 
In vitro SUMO modification of APC4 immunoprecipitated from stable 
inducible cell lines 
 We investigated whether APC/C complexes purified from stable 
inducible cell lines expressing Flag-APC4 (wild type) or Flag-APC4KR 
(double SUMO mutant) can be SUMO modified in vitro. Stable cell lines 
were treated with siRNA oligonucleotides to endogenous APC4 and induced 
with doxycycline for Flag-APC4 or Flag-ACP4KR expression for 48 hours. 
Cells were lysed using as described in Chapter 2. Cleared lysates were 
incubated with APC4 antibody (rabbit, A301-176A, 1:2000, Bethyl 
Laboratories, Inc) conjugated to Protein A AffiPrep Beads (BioRad). In vitro 
sumoylation reactions were performed as described in Chapter 1. Reactions 
were incubated at 37°C for the indicated times and stopped by addition of 2x 
SDS-sample buffer and analyzed by SDS-PAGE followed by 
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immunoblotting. Results demonstrate that APC4 but not APC4KR purified 
from human cells can be efficiently SUMO modified in vitro (Figure A-2). 
 
Characterization of APC4 Sumoylation Through Rapamycin-Mediated 
Heterodimerization 
 To control the temporal SUMO modification of APC4, we developed 
a system to induce heterodimerization between APC4 and the SUMO E2 
conjugating enzyme, Ubc9. A derivative of the rapamycin-mediated 
heterodimerization system1,2 was used as previously described3. This system 
uses a small, bivalent, cell-permeable compound (AP21967, Ariad 
Pharmaceuticals, Inc.) to induce dimerization between FKBP (FKBP506 
binding protein) and FRB proteins in vivo. Induced dimerization between 
APC4 wild type or APC4KR with induced fusion of the SUMO ligating 
enzyme Ubc9 would allow us to analyze downstream effects of APC4 
sumoylation. Plasmids expressing 3xFlag-APC4-FKBP or 3xFlag-APC4KR-
FKBP were co-transfected with FRB-Ubc9-HA (Figure A-3A). Following 
18 hours of transfection, 240 nM AP21967 was added to cells. Cells were 
lysed for analysis by SDS-PAGE and immunoblotting (Figure A-3B) and 
prepared for immunofluorescence microscopy (Figure A-3C). 
Immunoblotting using an antibody specific for Flag (M2, 1:2000, Sigma-
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Aldrich) indicates that heterodimerization of 3xFlag-APC4-FKBP with 
FRB-Ubc9-HA efficiently SUMO modified APC4, as indicated by the 
upshifted band at ~120 kDa (marked by *), while 3xFlag-APC4KR-FKBP did 
not. Immunoblots specific for HA (mouse, Santa Cruz Biotechnology, Inc.) 
indicate expression of FRB-Ubc9-HA. Immunofluorescence microscopy 
analysis shows that upon treatment with heterodimerizer, both 3xFlag-
APC4-FKBP and 3xFlag-APC4KR-FKBP localize to the nuclear rim (Figure 
A-3C). Thus, drug-induced fusion with Ubc9 targets 3xFlag-FKBP-APC4 
and 3xFlag-FKBP-APC4KR to the nuclear periphery—likely to nuclear pore 
complexes. Under certain conditions, Ubc9 is targeted to the nuclear pore4, 
and we did not pursue subsequent analysis of APC4 sumoylation using this 
system due to this dimerization-induced change in localization.  
 
APC4SUMO is not targeted for proteosomal degradation 
 In the generation of Flag-APC4KR-SUMO2 doxycyline-inducible 
stable cell lines, we noticed that during single clone selection, induced 
expression of the SUMO2 fusion cell lines were always lower than Flag-
APC4 and Flag-APC4KR. Separate observations during immunopurifications 
with the single Flag tag were noted and hypothesized to have low affinity for 
Flag-conjugated Protein A beads. We replaced the single Flag with a 
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2xStrep sequence (Strep-Tag II sequence was used: WSHPQFEK), which 
has a high binding affinity to biotin-conjugated beads (Figure A-4). The 
same observation of low-expressing SUMO2 fusion clones was made with 
2xStrep-APC4 cells. Single clones expressing SUMO2 fusion were selected 
and induced with doxycycline for ~18 hours. To test of the SUMO2 tag was 
directing Flag-APC4KR-SUMO2 to ubiquitin-mediated proteasomal 
degradation, cells were treated with 20µM MG132 (proteasome inhibitor) 
for 4 hours. Cells were lysed and analyzed by SDS-PAGE followed by 
immunoblotting. As indicated by the asterisk (*), cells treated with MG132 
do not accumulate the APC4-SUMO2 fusion in comparison to cells without 
treatment (Figure A-4). These data suggest that the linear SUMO2 fusion 
does not get targeted for proteosomal degradation. However, why APC4-
SUMO2 is never expressed at high levels is still an outstanding question. 
 
The C-terminus of APC4 Binds to Ube2S in vitro 
 The APC/C has two characterized ubiquitin E2 ligases that bind and 
interact to catalyze substrate ubiquitylation. UbcH10 and Ube2S5 are 
required for efficient catalysis. Interestingly, Ube2S was reported to be 
critical for the metaphase-anaphase transition, with similar mitotic defects as 
APC4KR 6. Furthermore, Ube2S was reported to have a positively charged C-
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terminal tail7 that is functionally required for APC/C activity. Intriguingly, 
the C-terminus of APC4 contains a stretch of negatively charged residues 
which reside in close proximity to the SUMO consensus sites (Figure A-5). 
We hypothesized that SUMO modification of APC4 may interfere with an 
interaction between the positively charged Ube2S and the negatively 
charged APC4 C-termini. First, we tested the binding interaction between 
recombinant Ube2S and APC4 (Figure A-5). Recombinant GST-Ube2S was 
expressed in pGEX-6P-1 expression vector and transformed into E. coli 
strain BL21. Cultures were grown to an OD = 0.7 and induced with 1 mM 
IPTG for 16 hours at 20°C. Cells were resuspended in 4°C lysis buffer (40 
mM Tris-Hcl pH 8.0, 500 mM NaCl, 1 mM Dtt, 0.4% TNS-100, Roche 
complete protease inhibitor cocktail, 1 mM PMSF, 100 µM leupeptin, 
1µg/mL peptatin A, 20 µg/mL aproptinin, and 10 U/mL benzomase) and 
sonicated on ice. Insoluble material was removed by centrifugation at 14,000 
rpm and supernatants were run over pre-packed glutathione-agarose 
columns. The C-terminus of APC4, spanning amino acids 554-808 (Figure 
A-5), was also expressed and purified in pGEX-6P-1 vectors, but the GST 
tag was cleaved with PreScission Protease, overnight at 4°C. Eluted proteins 
were further purified using size exclusion on a Superdex 75, in buffer 50 
mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, and 1 mM DTT. In 
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vitro binding assays were performed with 1µM GST only or 1µM GST-
Ube2S bound to glutathione agarose. After a blocking reaction containing 
2% BSA in assay buffer (20 mM HEPES-KOH pH 7.3, 110 mM potassium 
acetate, 2 mM magnesium acetate, 0.05% Tween-20), a binding reaction 
with 1µM APC4 C-Terminus was performed for 3 hours at room 
temperature. Following several washes with assay buffer, proteins were 
eluted in 2x Sample Buffer and analyzed by SDS-PAGE followed by 
immunoblotting. Antibodies specific to GST and APC4 were used. Our 
results indicate that the C-terminus of APC4 binds to Ube2S (Figure A-5B 
shows GST- GST-Ube2S inputs, and Figure A-5C shows GST-Ube2S + 
APC4 binding). These experiments were performed prior to structural 
studies, which placed Ube2S in close proximity to APC4. Recently, the 
binding interactions between Ube2S and APC4 have been confirmed. The C-
terminal tail of Ube2S is shown to bind to APC4 at amino acids 747-7518 
which is included in our C-terminal fragment but 20 amino acids away from 
the first SUMO consensus site lysine (772). 
 
Affinity chromatography with Recombinant APC4C-term with HeLa S3 
cell extracts 
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 To take an unbiased approached towards identifying potential 
substrates that uniquely interact with sumoylated APC4, we immobilized 
recombinant APC4 and in vitro sumoylated APC4 and incubated with HeLa 
whole cell extracts (Figure A-6). First, recombinant MBP-APC4C-term was 
expressed and purified as described above but using amylose resin for 
affinity purification. In vitro sumoylation reactions were performed as 
described above with 1 µM recombinant SUMO1 and 2 µM of recombinant 
MBP-APC4 at 37°C for 2 hours. MBP-APC4 or MBP-APC4SUMO was then 
immobilized onto amylose resin with assay buffer (20 mM HEPES KOH pH 
7.0, 110 mM potassium acetate, 2 mM magnesium acetate, and 0.05% 
Tween-20) for 2 hours at 4°C. HeLa S3 cell lysates were prepared from a 1 
L suspension. The cell pellet was lysed by sonication on ice in assay buffer 
supplemented with a Roche Protease Inhibitor Tablet, phosphatase inhibitor 
cocktail (PhosStop, Sigma-Aldrich), 1 mM PMSF, and 10 mM NEM. 
Insoluble material was removed by centrifugation at 70,000 x g and filtered 
through a 0.44 µm PVDF membrane. Total soluble protein concentration 
was measured by a bicinchoninic assay (BCA) and 100 mg was incubated 
with either MBP-APC4 or MBP-APC4SUMO1 for 1 hour at 4°. After several 
washes with assay buffer, elutions were performed with 1 M maltose and run 
on SDS-PAGE followed by silver staining. Compared to MBP-APC4, the 
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MBP-APC4SUMO1 appears to have distinct bands (indicated by asterisks*). 
Future analysis using full length APC4 may lend insight to the SUMO-
specific interactions of APC4, as it is still yet unknown whether APC/C 
substrate selection is determined by sumoylated APC4.   
 
Concluding Remarks and Future Directions 
  Our investigation on how the SUMO pathway affects the metaphase-
anaphase transition led us to the characterization APC4 sumoylation and the 
molecular mechanism of how SUMO modification of this subunit stimulates 
APC/C activity. Here we describe the initial approaches used to generate 
hyper-sumoylated APC4 in vitro and in vivo. The findings from these 
supplementary experiments led us to the body of work described in Chapter 
2. Future work on whether APC4 sumoylation perturbs Ube2S binding will 
be an interesting question to pursue. However, recombinant complexes of 
APC/C—which is composed of more than 15 subunits in varying 
stoichiometry—will be a better substrate to use for binding assays. The 
interactions between two subunits is limiting and does not account for 
interactions as they occur in vivo. Recent methods papers have described a 
methodology for creating recombinant APC/C, and will be a useful reagent 
to use in future work9. Affinity chromatography using MBP-APC4 and 
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MBP-APC4SUMO1 as bait presents an unbiased direction for the future of this 
project. It is yet unknown whether SUMO modified APC4 recruits specific 
substrates to the APC/C, or whether SUMO modified APC4 recruits the 
APC/C efficiently to kinetochores.  
 The evolution of this project was influenced by the technological 
leaps in the field of tomography made in the past decade. The advancements 
in Cryo-EM tomography have produced structures at atomic resolution of 
the APC/C8,10–16. A snapshot of the structure from 2005 places the 
coactivator Cdh1 close to the APC2 cullin domain17 (Figure A-7). In the 
middle of my PhD, structures at or near atomic resolution re-positioned 
Cdh1 close to the Tpr repeat regions of APC3 and APC715 (Figure A-7). 
These studies further revealed flexible, disordered regions in APC4 and 
APC2 that energized us to pursue mechanistic studies. Of note, the C-
terminal sumoylation consensus site lysines are in a disordered region that is 
not resolved in any of the current structures. We hypothesize that SUMO 
modification of APC4 stabilizes this C-terminal domain, limiting the degrees 
of freedom for both the APC2 cullin domain as proposed in our model 
(Figure 2-8) and the C-terminal tail of APC4. Finally, inhibitors of the 
APC/C for cancer therapeutics are currently in development13,18. It is of 
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particular interest to determine if the sumoylation site on APC4 is a unique 
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SENP1 depletion results in enhanced APC4 SUMO modification 
 HeLa cells were treated with either a control or SENP1 siRNA 
targeting oligo for 48 hours, followed by a double thymidine block (using 2 
mM Thymidine). Cells were released and harvested at indicated timepoints 
and analyzed by immunoblotting using antibodies specific for APC4, Cyclin 
B1, Phosphorylated Histone H3 (PH3), SENP1, and GAPDH as a loading 











In vitro SUMO modification of APC4 immunoprecipitated from stable 
inducible cell lines 
 Stable inducible cell lines expressing APC4 or APC4KR were induced 
for 48 hours using doxycycline, with concomitant depletion of endogenous 
APC4 using an siRNA targeting oligo to the 3’UTR of APC4. Cells were 
lysed and APC4 was immunoprecipitated using GaDDDK antibody (Bethyl, 
2 µg antibody for 1 mg cell lysate, based on BCA quantification) conjugated 
to Protein A AffiPrep beads (BioRad). In vitro sumoylation reactions were 
performed using recombinant SUMO E1 and SUMO E2 enzymes, and 
SUMO-1 or SUMO-2 protein at 37°. Reactions were stopped at indicated 
timepoints using 2x Sample Buffer and immunoblotting was performed 
using an antibody specific for APC4. Asterisks indicate SUMO modified 













Characterization of APC4 Sumoylation Through Rapamycin-Mediated 
Heterodimerization 
(A) A plasmid expressing 3xFlag-APC4 wild type (WT) or double SUMO 
mutant (KR) with a linear FKBP tag was co-expressed with a plasmid 
expressing FRB-Ubc9-HA in HeLa cells using Lipofectamine 2000 reagent 
according to manufacturer’s protocols (Thermo Fisher Scientific). (B) 
Following 24 hours of transfection, heterodimerization reagent was added. 
Following 48 hours of transfection and 24 hours of heterodimerization, cells 
were harvested using 2x Sample Buffer, and analyzed using SDS-PAGE 
followed by immunblotting analysis with antibodies specific for Flag (Flag 
M2, 1:2000, Sigma) and HA (rabbit, Y-11, 1:1000, Santa Cruz). (C-F) 
Immunofluorescence analysis of cells expressing 3xFlag-APC4 WT or KR 
and FRB-Ubc-HA in the absence or presence of heterodimerizer was 
performed following fixation with 2% formaldehyde and permeabilization 
with 0.2% TNX-100. Antibodies specific for Flag (M2, 1:400, Sigma), HA 
(rabbit, Y-11, 1:300, Santa Cruz), and counterstaining with DAPI to 








APC4SUMO is not targeted for proteosomal degradation 
 Stable inducible cell lines expressing N-terminal 1xFlag or 2xStrep 
tags followed by APC4KR-SUMO2 were treated with doxycycline to induce 
transgene expression for 48 hours. Following 24 hours of doxycycline 
induction, cells were treated with 4 µM MG132 to inhibit proteasome 
activity and to monitor protein stability. Cells were lysed in 2x Sample 
Buffer and analyzed by SDS-PAGE followed by immunoblotting with an 







The C-terminus of APC4 binds to Ube2S in vitro 
(A) Recombinant proteins were expressed and induced in E. coli. A linear 
fusion of GST-Ube2S (full length) contains a stretch of positively charged 
amino acid residues (indicated by K – lysine – highlighted in blue) in the C-
terminal end. The C-terminus of APC4, including amino acids 554-808, was 
expressed and purified from E. coli. A C-terminal domain contains a stretch 
of negatively charged amino acid residues (indicated by D and E – aspartic 
and glutamic acids – highlighted in pink). (B) In vitro binding assays were 
performed using GST-Ube2S or GST as a positive control immobilized on 
glutathione beads (Pierce). Binding reactions with recombinant C-terminal 
APC4 were analyzed by SDS-PAGE followed by immunoblotting with 
antibodies specific for GST (mouse, 1:500, SC-138, Santa Cruz 















Affinity chromatography with recombinant APC4C-term with HeLa S3 
cell extracts 
 Recombinant MBP-APC4 (C-terminal amino acids 554-808) were 
expressed and purified in E. coli. MBP-APC4 was SUMO modified using 
recombinant SUMO E1 and E2 enzymes and recombinant SUMO1 protein. 
MBP-APC4 or MBP-APC4SUMO1 was immobilized onto amylose resin (New 
England Biolabs) for in vitro binding reactions with 1 mg of total protein 
(determined by BCA) extracted from HeLa S3 cells. MBP-APC4 or MBP-
APC4SUMO1 was eluted using 1 M maltose and proteins were analyzed by 
SDS-PAGE followed by silver staining. Asterisks indicate potentially 



















Analysis of Cryo-EM strucutres of the APC/C 
 Cryo-EM structures of the APC/C solved by Dube et al. in 2005 and 
Chang et al. in 2015 show the advances in resolution achieved over time in 












OVERVIEW AND FUTURE DIRECTIONS 
 
 Mitosis is an essential cellular process that is coordinated by several 
axes of regulation. At the onset of nuclear envelope breakdown, a robust 
signaling cascade is initiated, involving the activity of mitotic kinases like 
Cdk1 so that appropriate alignment and amphitelic microtubule-kinetochore 
interactions are achieved. Unattached kinetochores generate the Spindle 
Assembly Checkpoint (SAC), a “wait anaphase” signal to inhibit the activity 
of the Anaphase Promoting Complex/Cyclosome (APC/C).  The metaphase-
anaphase transition is a time when SAC signaling is attenuated and the 
activity of the APC/C is stimulated to ubiquitylate substrates like Cyclin B1 
and securin. Precisely how the “rheostat3” in the mitotic cell receives inputs 
from the SAC to “tune up” inhibitory signals against APC/C activity is still 
an unanswered question.  
 Chapter 2 describes one mechanism of how the activity of the APC/C 
is stimulated through the SUMO modification of the APC4 subunit. SUMO 
modification of APC4 facilitates novel non-covalent interactions with the 
SIM (SUMO interacting Motif) in the cullin subunit APC2 of the APC/C. 
Based on our model, this SUMO-SIM interaction stabilizes a conformation 
of the APC/C that limits the degrees of flexibility in APC2, and positions 
this catalytic subunit towards optimal configurations for binding the 
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ubiquitin-charged E2 enzyme, UbcH10. Binding of the ubiquitin-charged E2 
to the APC/C is a critical step that is followed by the efficient transfer of 
ubiquitin to substrates so that mitotic exit can be correctly achieved. We 
propose that SUMO modification of APC4 thus stimulates UbcH10-
dependent catalysis of the APC/C. 
 We have identified that the second E2 enzyme that cooperates with 
the APC/C, Ube2S, binds to the C-terminus of APC4. Future work on 
characterizing the mechanistic effects of APC4 sumoylation on Ube2S is of 
particular interest. Furthermore, it is still unknown how the inhibitory 
mitotic checkpoint complex (MCC) generated by the SAC is disassembled 
or released from the APC/C. Although the APC152 subunit and the activity 
of AAA-ATPase3 have been implicated, it is compelling to consider the role 
of SUMO in this process. The APC/C adopts a distinct conformation upon 
MCC binding and release, and whether the sumoylation of APC4 contributes 
to this process is a key area of inquiry. Expression and purification of 
recombinant complexes of the APC/C will be valuable in biochemical assays 
to address these questions. Recent papers have described a methodology for 
creating recombinant APC/C, which will be a useful reagent to use in future 
work1. Our cellular assays demonstrate that a single SUMO fusion is 
sufficient for restoring normal metaphase-anaphase transitions, thus a 
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recombinant APC/C complex can include a linear SUMO fusion to the C-
terminus of APC4. 
 The evolution of this project was influenced by the technological 
leaps in the field of tomography made in the past decade. The advancements 
in Cryo-EM tomography have produced structures at atomic resolution of 
the APC/C5–10. A snapshot of the structure from 2005 places the coactivator 
Cdh1 close to the APC2 cullin domain11 (Figure A-7). In the middle of my 
PhD, structures at or near atomic resolution re-positioned Cdh1 close to the 
Tpr repeat regions of APC3 and APC712 (Figure A-7). These studies further 
revealed flexible, disordered regions in APC4 and APC2 that energized us to 
pursue mechanistic studies. Of note, the C-terminal sumoylation consensus 
site lysines are in a disordered region that is not resolved in any of the 
current structures. Whether SUMO medication of APC4 stabilizes this 
disordered region, and the verification of interactions with the SIM in APC2 
is of key future interest. Furthermore, inhibitors of the APC/C for cancer 
therapeutics are currently in development13,14. It is of particular interest to 
determine if the sumoylation site on APC4 is a unique druggable target. 
Structural studies using cryo-EM will be one approach towards addressing 
these outstanding questions.  
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 It is yet an unknown whether SUMO modification can also recruit 
specific substrates to the APC/C for ordered ubiquitylation and protein 
degradation. In an unbiased approach towards addressing whether 
sumoylated APC4 has unique affinities to soluble proteins, affinity 
chromatography using MBP-APC4 and MBP-APC4SUMO1 as bait with whole 
cell lysates was performed (Figure A6). Analysis from this experiment 
suggests that the SUMO-modified C-terminal tail of APC4 interacts with 
distinct proteins compared to unmodified APC4, and identification and 
characterization of these proteins will be an interesting avenue to pursue. 
 Chapter 3 proposes another mechanism of how the SUMO pathway 
“tunes up” inhibitory SAC signaling. First, we demonstrate that localization 
of the SUMO isopeptidase SENP1 to the nuclear pore complex during 
interphase is regulated by specific N-terminal sequences. Characterization 
by immunofluresence microscopy, supported by BioID analysis, indicate 
that SENP1153-272 interacts with the Nup107 complex and SENP1274-449 
interacts with the Tpr subunit at the nuclear pore. Functional assays suggest 
that SENP1 interactions with Nup107 are required for normal mitotic exit, as 
SENP1 depletion results in delays during the metaphase-anaphase transition. 
SENP1 depletion also results in the accumulation of the SAC proteins Mad1 
and Mad2 at the nuclear pore during interphase. This pre-assembled 
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checkpoint complex has been implicated in regulating mitotic timing15. 
Whether a distinct, soluble pool of checkpoint complexes are generated 
during interphase to fine tune APC/C activity is an area of future 
investigation. Gel filtration of whole cell lysates that separate soluble pre-
assembled checkpoint complexes in control or SENP1 depleted cells is a key 
first step in pursuit of this mechanistic study. 
 SUMO modification is conserved from yeast to humans. While lower 
eukaryotes only express a single SUMO paralog, vertebrates express several 
SUMO isoforms16. Genetic knockouts of individual SUMO genes in mice 
demonstrate that SUMO1 and SUMO3 are dispensable, while SUMO2 is 
not17,18. This is due in part to the relative level of SUMO expression in mice; 
Sumo3 mRNA only accounts for 2% of total Sumo mRNA in E7.5 and E8.5 
mouse embryos, while Sumo2 accounts for 80% of total Sumo mRNA18. 
Whether the relative expression levels of SUMO2 and SUMO3 in human 
cells is similar is yet unknown.   
 Broadly, work over the past decade has shed significant insights into 
how SUMO2/3 regulate mitotic progression, as discussed in Chapter 1 of 
this thesis. High throughput proteomic studies have already identified 
thousands of SUMO substrates, including those uniquely regulated during 
mitosis19,20. Of the thousands of SUMO substrates identified, a relatively 
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small fraction has been validated, and many defined molecular mechanisms 
support a model of sumoylation as “molecular Velcro21.” However, future 
endeavors focused on additional SUMO substrates may lead to novel 
discoveries and new models of how sumoylation regulates cellular functions. 
 The APC/C is a molecular machine that is highly conserved in all 
eukaryotes, and the APC2 and APC4 subunits are also highly conserved. 
However, the sumoylation sites on the APC4 subunit of the APC/C are only 
conserved in vertebrates (Figure 3-4A). Interestingly, the SIM motif in the 
APC2 subunit are also only conserved in vertebrates (Figure 3-8B). This 
suggests that sumoylation of the APC4 subunit co-evolved with a receptor 
for SUMO, in the form of a SIM in the APC2 subunit. While work from this 
thesis suggests that SUMO modification of APC4 is critical for catalytic 
activity of the APC/C through non-covalent interactions with the cullin 
subunit, APC2, it is interesting to consider whether there are additional 
functional roles for sumoylated APC4. Specifically, whether the assembly of 
the APC/C, a multi-subunit E3 ligase, requires SUMO modification is an 
intriguing question to consider. The catalytic APC2/11 module has been 
previously shown to dissociate from the rest of the core APC/C under 
conditions of high salt or acidic pH22. Whether the entire catalytic arm is 
dynamically associating and dissociating from the APC/C is yet an 
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unanswered question, and whether SUMO modification of APC4 – which 
comprises part of the stable platform domain of the APC/C – is an intriguing 
question to consider.  Finally, why eukaryotes require additional 
regulatory features in the mitotic apparatus, including additional kinases and 
components of the SUMO pathway, is an over-arching question. Perhaps the 
complexity of mitosis in vertebrates, or the requirement of mitotic fidelity to 
maintain longer lifespans in high order organisms, necessitates additional 
levels of regulation by post-translational modifications. Taken together, the 
vignettes of APC4 sumoylation in regulating metaphase-anaphase 
transitions, and the regulatory role of the SUMO pathway in regulating 
mitotic progression in human cells presented in this thesis, provide a glimpse 
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